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ABSTRACT
Induced pluripotent stem (iPS) cells have unparalleled potential for disease
modeling and use in regenerative medicine but are plagued with genetic instability and
tumourgenicity. Small molecules including histone deactylase inhibitors and DNA
methylation inhibitors, as well as use of more undifferentiated cell types as source
material, have been used to increase the efficiency and safety of reprogramming by
necessitating fewer exogenous pluripotency factors. Human multi-lineage progenitor
cells (hMLPCs), derived from post-partum umbilical cord blood, and human dermal
fibroblasts (hDFs) were examined for both RNA expression and protein localization of
pluripotency factors OCT4, SOX2, KLF4 and Nanog before and after 7-day treatment
with s-adenosylhomocysteine (SAH), valproic acid (VPA), and basic fibroblast growth
factor (bFGF). Untreated hMLPCs and hDFs expressed pluripotency factor mRNA but
only KLF4 in hDFs, and KLF4/SOX2 in hMLPCs were detected at the protein level.
SAH-treatment resulted in detection of Nanog protein in hMLPCs, solely in the presence
of SOX2, without change in RNA transcript levels, indicating an important posttranscriptional role, which may act via the positive autoregulatory loop of OCT4,
NANOG and SOX2 that is crucial for maintaining the undifferentiated state. Due in part
to the synergistic autoregulatory relationships between endogenously expressed SOX2
and other pluripotency factors, hMLPCs may be more amenable to reprogramming.

Key Terms: Induced pluripotent stem (iPS) cell, umbilical cord blood (UCB), progenitor
cell, basic fibroblast growth factor (FGF), fibroblast growth factor receptor (FGFR),
regenerative medicine, embryonic stem (ES) cell, epigenetics, acetylation, methylation,
valproic acid (VPA), s-adenosylhomocysteine (SAH), small molecule.
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW
1.1 The burden of injury and degenerative disease
The capability of the human body to heal itself against insults and injury is
amongst the most important faculties that we possess. To achieve healing, the damaged
tissue undergoes either: i) regeneration where the functional cells of the tissue present
prior to injury are replaced and returned to normal function, or ii) repaired where
compromised tissue is replaced by non-functional cells or scar tissue. Healing via
regeneration is only possible when the cell types of the injured tissue have the ability to
replicate and migrate to replace destroyed cells. The most notable organ tissue that heals
readily is the liver (Chauhan, et al., 2011), which has been demonstrated to regenerate
from only 20% of the remaining mass following partial hepatectomy (Nardo, et al.,
2011). Regeneration, however, is largely due to the compensatory growth of hepatocytes
and will return mass and most function, not form. Tissue re-growth is also age-related. In
many tissue types, the biological age of the patient is directly correlated to the ability to
regenerate lost or damaged tissues (Suzuki, et al., 2010; Yanai, et al., 2011). There are
certain tissues and cell types that, regardless of age, are limited in their ability to
regenerate. These include but are not limited to cardiac tissue, neural cells and hormoneproducing islets of Langerhans of the pancreas.
The limited capacity of cardiac cells to regenerate after ischemic insult caused by
myocardial infarction, better known as a ‘heart attack’, can result in the production of
scar tissue, which constricts movement in the weakened muscle tissue of the heart further
impeding the ability of the heart to transport oxygen-rich blood (Khan, et al., 2011).
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Many neural injuries and disorders are caused by either direct or indirect insults to
the central nervous system’s network of functional neurons and supportive neuroglia cells
that includes the brain, spinal cord and retina. These can be caused by a number of factors
including genetic defects, physical damage due to direct trauma or secondary swelling,
infection, or aging. If neural signaling pathways are disrupted an important
electrochemical communication circuit of the body could be compromised resulting in
loss of sensory and/or motor function, including appendage or organ muscle function, or
in more extreme cases, complete paralysis below the point of injury. Reinnervation is
possible, but the glial scarring that results from injury often blocks the ability of nerves to
re-connect the severed column (R. Hu, et al., 2010).
The islets of Langerhans are the hormone-producing cell clusters of the pancreas,
which contain, among other cells types, insulin-producing beta cells. In polygenic
susceptibility type I diabetes, these beta cells are destroyed leading to increased blood
and urine glucose causing hypoglycemia-induced fatigue and long-term damage to
internal organs (Nathan, 1993). Currently, insulin injections are the most common type of
treatment. Independence from these injections is possible with whole islet transplantation,
yet low donor islet availability and low rates of long-term post-transplantation cell
survival limit the effectiveness of this strategy (Ryan, et al., 2005).
From these few examples, it is clear that the human body is not capable of
sufficiently regenerating all of its specialized cell types to restore function in damaged
tissues. One option to achieve this is to harness the replicative capacity of other
therapeutic cell types.

3
1.2 Regenerative Medicine and Stem cells
1.2.1 Regenerative Medicine
Regenerative medicine is the process by which functional tissues capable of
repairing or replacing tissue or organ function lost due to damage, age, disease, or
congenital/degenerative defect are created to regenerate previously irreplaceable tissues
(Nauta, et al., 2011). Regenerative medicine holds the promise of decreasing the donor
organ shortage and eliminating risk of immune rejection, where the transplanted tissues
are the patient’s own cells. Healthy cells are harvested from the body and grown ex vivo
and re-transplanted as tissue-engineering grafts. This process has been successfully
implemented in many tissue types including epithelial (Gomez, et al., 2011; Watanabe, et
al.), bone (Mangano, et al.; Susarla, et al., 2011) and cartilage (Dhollander, et al., 2010)
tissues. Stem and precursor cells, available from a wide variety of sources (embryos,
gestational and adult tissues, and reprogrammed differentiated cells), have the potential to
increase the range and efficacy of engineered tissues and to treat many intractable
diseases.

1.2.2. Embryonic Stem Cells
Cells with limitless replicative capacity and the ability to repair or replace
degenerating or damaged tissue are necessary for advancements in regenerative medicine.
During mammalian development the totipotent cells of the early embryo differentiate into
multiple populations: 1) the trophectoderm, which will become the extra-embryonic
layers of the placenta, 2) the extra embryonic endoderm, which will become the yolk sac
and 3) the inner cell mass (ICM), which will generate all 3 germ layers of the embryo
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(Figure 1.1). The exact timing and mechanisms of early development in humans is not
known due to the ethical complications and availability of source material, and is based
upon known development of the mouse fetus (Cockbum & Rossant, 2010).

Placenta

Figure 1.1 Embryonic and extra-embryonic structures resultant of blastocyst cell
lineages. The inner cell mass (ICM), which during later development becomes the
epiblast and primitive endoderm, gives rise to the embryo proper while the trophoblast
will eventually form the placenta.

To generate embryonic stem cell lines the ICM of the preimplantation blastocyst
can be harvested and placed on either mitotically inactivated mouse embryonic
fibroblasts (MEFs) or an extracellular protein matrix in defined or MEF-conditioned
media, which contains critical secreted factors without cell materials or debris, for
isolated stem cell culture (A. Choo, et al., 2006; Stewart, et al., 2008) (Figure 1.2). The
first embryonic stem (ES) cells were derived from blastocyst-stage mouse embryos and
were a result of the successful optimization of both developmental stage harvesting and
tissue culture conditions. The resultant cells were capable of unlimited replication and
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maintenance of the pluripotent state (Evans & Kaufman, 1981). Culture conditions
include medium supplemented with Leukemia-inhibitory factor (LIF), and equal parts
fetal calf serum and newborn calf serum. The cells were also cultured on a monolayer of
MEFs. The successful derivation o f mouse ES cell lines was followed by the isolation of
a non-human primate ES cell line (Thomson, et al., 1995). Deriving non-human primate
ES cells paved the way for embryonic stem cells lines derived from human blastocysts
(Thomson, et al., 1998).
hES cell lines, capable of long-term self-renewal, are pluripotent and can
therefore be differentiated into various differentiated cell types that arise from the three
germ layers (endoderm, mesoderm and ectoderm) making them theoretically capable of
forming all the cell types of the human body. The maintenance of these pluripotent cells
requires specific culture conditions including basic fibroblast growth factor (bFGF) the
use of MEFs to provide not only a protein matrix substrate for the cells to adhere and
grow on but also a source of critical growth factors that are essential for the maintenance
of pluripotency (Figure 1.2). Xeno-ffee products have been developed for animal-free
maintenance of hES cells, which is essential if they are to be used for clinical applications
(Fu, et al., 2011). These products expand on the natural tendencies of human embryonic
stem cell colonies to have their peripheral cells differentiate into fibroblast-like cells,
which secrete hES cell supportive factors including bFGF (Amit, et al., 2000; Moogk, et
al., 2010; Y. Park, et al., 2011).
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hESC colony

Figure 1.2 The generation and maintenance of hES cell lines. The inner cell mass of
the blastocyst (embryonic day 8) is isolated and cultured on either a mouse embryonic
fibroblast (MEF) layer or extracellular matrix in MEF-conditioned media. For xeno-ffee
culture conditions human dermal fibroblasts (hDFs) can be used in place of MEFs. The
differentiation of ES cells into fibroblast-like cells occurs at the perimeter of the colonies
(Moogk, et al., 2010).

1.2.3 Adult Stem Cells
Alternative to the use of ES cells in regenerative therapies are multipotent stem
cells, also referred to as adult stem cells or somatic stem cells. In contrast to ES cells,
adult stem cells are capable of self-renewal can differentiate to yield some or all of the
major specialized cell types of the tissue or organ (Korbling & Estrov, 2003). These
undifferentiated cells are found among terminally differentiated cells in a tissue or organ
and can differentiate to generate some or all of the specialized cell types of the tissue.
Their primary function in a living organism is to maintain and repair the tissue in which
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they are located. Adult stem cells are much more widespread than initially thought, and
have been identified in many tissues including brain (Walton, 2011), skin (Sieber-Blum,
2011), bone marrow (Badiavas & Badiavas, 2011; Wirthlin, et al., 2008), teeth
(Nakahara, 2011), peripheral blood (Ye, et al., 2011), blood vessels and skeletal muscle
(Mounier, et al., 2011), heart (Martin-Puig, et al., 2008), liver (Cardinale, et al., 2011),
ovarian epithelium (Bukovsky, 2011), and testis (Spradling, et al., 2011). Adult
hematopoietic stem cells have been transplanted for fifty years in the form of bone
marrow allogenic transplantation (Terzic, et al., 2011). Autologous transplantation of
bone marrow stromal stem cells have also successfully been used to treat critical limb
ischemia in diabetic patients (Dubsky, et al., 2011). A more recently recognized rich
source of adult stem cells with potential for use in regenerative medicine is in umbilical
cord blood (Forraz & McGuckin, 2011). The use of umbilical cord blood as a source of
adult stem cells is gaining popularity due to its ease of access at the time of birth, the
concentration of these young, immunologically naive cells, and the recent advances in
technology for the large-scale cell separation, with high throughput, yield and purity
(Sousa, et al., 2011). Somatic stem cells have also been used to treat many previously
incurable disorders and diseases using stem cell-based tissue engineering including
myocardial infarcts (Nunes, et al., 2011), Multiple Sclerosis (Odinak, et al., 2011), and
even are being proposed as a treatment for retinal degradation-induced blindness (Singh
& Maclaren, 2011).
For the most part, somatic stem cells exist in what is termed the ‘stem cell niche’,
a microenvironment necessary for the maintenance of stem cells within a tissue with
variable structure and cell types unique to the type of adult stem cell (L. Li & Xie, 2005).
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The niche not only functions as a physical anchor for the stem cells, but also generates
extrinsic factors that control stem cell fate and number. Many growth factors and
signaling peptides have been shown to be involved in regulation of stem cell behavior,
including hedgehog, Wnts, bone morphogenetic proteins, fibroblast growth factors,
Notch, and leukemia inhibitory factor, each with different but complementary roles in
regulating stem cell self-renewal, proliferation, migration, and lineage commitment (L. Li
& Xie, 2005). The presence of signaling components of multiple conserved
developmental regulatory pathways in stem cells found in mammalian bone marrow, hair
follicle, intestine, brain, and testis, supports the theory that adult stem cells retain the
ability to respond to embryonic regulatory signals relating to stem cell self-renewal and
lineage commitment (L. Li & Xie, 2005). Adult stem cells can remain quiescent for long
periods of time until they are stimulated to maintain or repair tissues damaged by injury
or disease (Sieber-Blum, 2011). Upon activation of stem cell proliferation, one daughter
cell is typically maintained in the niche as a stem cell while the other leaves the niche to
proliferate and differentiate becoming a functionally mature cell in a process known as
asymmetric cell division.

1.3 Pluripotency
1.3.1 Mechanisms o f self-renewal and pluripotency factors
Stem cell populations require a balance between survival, proliferation, and selfrenewal signals. The regulation of these processes depends on many interacting pathways
that are influenced by extracellular signaling, transcription factors, cell-cycle regulation
and epigenetic regulators (N. Liu, et al., 2007). In eukaryotic cells, transcription factors

9
activate gene expression by recruiting the transcription machinery and/or by stimulating
the release of RNA polymerase II (Fuda, et al., 2009). Chromatin regulators can also be
recruited to promoter regions to modify and mobilize nucleosomes in order to increase
access to DNA for transcription (B. Li, et al., 2007; Sexton, et al., 2007). The
transcription factors known to be responsible for maintaining the undifferentiated state of
the human ES (hES) cells are Nanog, OCT4 and SOX2 (Young, 2011). In hES cells,
SOX2 and OCT4 cooperatively drive pluripotent-specific expression of several genes,
including Nanog, by binding to their promoters and thus regulating the expression of
downstream pluripotent genes (Rodda, et al., 2005; Young, 2011). KLF4 has also been
indicated as a regulator of Nanog expression in hES cells helping to prevent
differentiation (P. Zhang, et al., 2010). OCT4, SOX2, and Nanog interact with
coactivators that bind to RNA polymerase II (Kagey, et al., 2010) and cooperatively
activate a considerable proportion of the actively transcribed protein-coding and
microRNA genes in hES cells, including some of their own promoters (Young, 2011).
Other important stem cell regulatory genes include Tcf3, Smadl, Stat3, Esrrb, Sall4,
Tbx3, Zfx, Ronin, Klf2, KLF4, Klf5, and PRDM14 which have been shown to play
important roles in the control of the hES cell state by augmenting the function of the core
transcription factors at actively transcribed target genes. Downregulation of these genes is
associated with a loss of pluripotency (Young, 2011).
Gene expression is also regulated by chromatin condensation around histones.
Initially regarded as simple structural elements, histones are now recognized as integral
components for the regulation of gene transcription. Histone post-translational
modifications, including covalent attachment of methyl or acetyl groups to lysine and
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arginine amino acids, play a vital role in influencing histone-DNA and histone-histone
interactions and thus the structure and transcriptional status of the DNA (Komberg &
Lorch, 1999). hES cell chromatin is characterized by several attributes that distinguish it
from that of differentiated cells and enable the cells to maintain their pluripotent nature,
including a less condensed and hyper-dynamic chromatin architecture (Meshorer, et al.,
2006), and a unique histone modification pattern enriched for histone modifications
associated with transcriptional activation (Gaspar-Maia, et al., 2011).

1.3.2 Histones
Reassigning cell fate depends greatly on the chromatin structure of the DNA,
which provides epigenetic regulation of gene expression. Within the eukaryotic nucleus,
this is accomplished via the association of DNA with histone proteins forming the
nucleosome, a 147-base pair stand of DNA wrapped 1.7 times around an octamer unit of
histone containing two H2A-H2B dimers and a H3-H4 tetramer (Komberg & Lorch,
1999). Histone N-terminal segments can be subject to several different post-translational
modifications including acetylation, phosphorylation, ubiquination, and methylation
(Kouzarides, 2007). These modifications help determine if the chromatin is extended and
active (euchromatin) or condensed and inactive (heterochromatin). The location of
histone modifications will determine whether there will be a positive or negative effect
exerted on transcription of genes. Histone H3 is the most extensively modified of all
histone types and is important due to its sequence variants and variable modification
states, which are thought to play a role in the dynamic and long term gene regulation. The
acetylation o f lysine residues results in unfolding of chromatin and transcriptionally
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active euchromatin as it neutralizes the basic charge of lysine (Kouzarides, 2007).
Methylated histones have been implicated in heterochromatic repression, promoter
regulation and the propagation of a repressed state (Kouzarides, 2002). These epigenetic
modifications are also critical in directing cell fate and sustaining pluripotency (TorresPadilla, et al., 2007), with condensed chromatin as a major mechanistic barrier to the
induction of pluripotency (Plath & Lowry, 2011).

1.3.3 Histone acetylation and methylation
The acetylation of histones H3 and H4 are modifications associated with a more
transcriptionally active state of chromatin (Meshorer & Misteli, 2006). In most species,
the main acetylation sites for histone H3 include lysines 9, 14, 18 and 23. These
modifications are performed by a family of enzymes known as histone acetyltransferases
(HATs) (Komberg & Lorch, 1999). The removal of acetyl groups, by histone
deacetylases (HDACs), has been linked with transcriptional repression. Low levels of
HD AC inhibitors have been reported to increase pluripotency and maintain self-renewal
in ES cells (J. H. Lee, et al., 2004; Ware, et al., 2009). Histone 3 lysine 9 (H3K9)
acetylation has been shown to occur at higher levels in hES cells as compared to
differentiating cells (Bartova, et al., 2008). The histone deactylase (HDAC) inhibitor
valproic acid (VPA) has been shown to increase reprogramming efficiency (Huangfu, et
al., 2008a; Huangfu, et al., 2008b) (Figure 1.3) and globally increase H3K9 acetylation in
ES cells (Hezroni, et al., 2011).
H3 and H4 are the predominant histones modified by methylation, preferentially
occurring at lysines 4, 9 and 27 on H3 (Guillemette, et al., 2011; Strahl, et al., 1999).
H3K9 methylation is sufficient for initiating a gene repression pathway in vivo
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(Snowden, et al., 2002). Associated with transcriptional activation are the trimethylations of H3K4 and H3K36, and di-methylation of H3K36 (Efroni, et al., 2008).

A.

Figure 1.3 Epigenetic modification of chromatin. Chromatin structure is dynamically
regulated by histone and DNA modification enzymes. A. Chromatin is acetylated (A) by
histone acetyltransferases expanding the DNA quaternary structure. Deacetylation is
inhibited by valproic acid (VPA) helping to maintain a transcriptionally active state. B.
DNA méthylation is catalyzed by specific DNA methyltransferases. sadenosylmethionine (SAM) acts as a methyl donor to the DNA substrate in DNMTmediated DNA méthylation, resulting in the formation of s-adenosylhomocysteine
(SAH). SAH has a much greater affinity than SAM for the methyltransferases active site.
An intracellular and cellular accumulation of SAH will inhibit most cellular
methyltransferases leading to a more transcriptionally active state.
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1.3.4 DNA methylation
Another important determinant in transcriptional activation of genes is DNA
methylation. DNA methyltransferases (DNMTs) catalyze the addition of methyl groups
from s-adenosylmethionine (SAM) to DNA in most transmethylation reactions (Jeon, et
al., 2008) (Figure 1.3). The product of this reaction is s-adenosylhomocysteine (SAH), a
methionine cycle intermediate, which having a much greater affinity for the
methyltransferases active site than SAM, creates a negative feedback pressure that
inhibits DNA methyltransferases (W. J. Lee, et al., 2005). Therefore an intracellular and
cellular accumulation of SAH will inhibit most cellular methyltransferases leading to a
more transcriptionally active state. It has been reported that application of a DNA
methyltransferases

inhibitor

increased

reprogramming

efficiency

and

enabled

reprogramming using only OCT4 and KLF4 (Shi, et al., 2008a; Shi, et al., 2008b).

1.3.5 Basic fibroblast growth factors (bFGF) and bFGF receptors
Growth factors capable of promoting stem cell growth and replication are critical
to the maintenance of the pluripotent state. Principal among them are fibroblast growth
factors (FGF). In humans, twenty-two FGFs (1-14,16-23) have been discovered, which
can interact with four FGF (1-4) receptor (FGFR) tyrosine kinases to promote mitogenic,
differentiation, migration and survival responses (Baird, 1994; Mason, 1994; Omitz &
Itoh, 2001). Numerous FGF genes are expressed in early mammalian embryos, which
suggest significant roles in development (Yamaguchi & Rossant, 1995). The FGFs are
heparin-binding proteins and interactions with cell-surface associated heparin sulfate
proteoglycans have been shown to be essential for FGF signal transduction (Friesel &
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Maciag, 1995; Ibrahimi, et al., 2004). bFGF, also known as FGF2, is a critical component
of human embryonic stem cell culture medium, necessary for pluripotent cells to remain
in an undifferentiated state in both feeder-dependent and feeder-free culture systems (Y.
Liu, et al., 2006), as well as to regulate hES cell self-renewal (Levenstein, et al., 2006). It
has been reported that treatment with bFGF has the potential to induce endogenous
expression of stem cell genes in somatic cells, to prolong Nanog expression in
differentiating hES cells, as well as to stimulate the upregulation and nuclear
translocation of FGFRs (Page, et al., 2009; P. Yu, et al., 2011b). Five isoforms (18-34
kDa in size) of bFGF are derived from alternative initiation codons of a single mRNA.
The 18-kDa bFGF isoform is released from cells by a secretory pathway and mainly
regulates gene expression by binding to cell surface receptors. The four higher-molecular
weight isoforms of bFGF with molecular masses of 22- 34 kDa are localized exclusively
to the nucleus through two nuclear localization signals (Amaud, et al., 1999; Quarto, et
al., 1991). Through signals originating either intracellularly or extracellularly, bFGF can
stimulate rRNA transcription via stimulation the extracellular signal-regulated protein
kinase (ERK/MAPK) signaling cascade, and promote RNA polymerase I transcription (J.
Zhao, et al., 2003). It has further been demonstrated that 18-kDa bFGF directly regulates
rRNA transcription in the nucleolus (Claus, et al., 2003; Sheng, et al., 2004), which raises
the possibility that it may directly function in the nucleus and nucleolus (the location of
ribosomal RNA transcription), regulating ribosome biogenesis, a rate-limiting process in
cell growth (Sheng, et al., 2005).
bFGF also interacts through intermediaries to regulate the cell state via
downstream signaling pathways, including the Wnt signaling pathway in hES cells and
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induced pluripotent stem (iPS) cells (Ding, et al., 2011; Ding, et al., 2010). Activated by
the binding of FGFs, FGFRs and other receptor tyrosine kinases activate proteins
belonging to different downstream signaling pathways, such as ERK, Wnt and
PI3K/AKT(Zoumaro-Djayoon, et al., 2011), insulin-like growth factor (IGF) in hES cells
(Bendall, et al., 2007) and adult multipotent stem cells derived from human umbilical
cord blood (S. B. Park, et al., 2009) and by interacting with pluripotency-associated
proteins and transcription regulators, namely SOX2, Nanog and OCT4 (ZoumaroDjayoon, et al., 2011). Structure is highly conserved between members of the FGFR
family. Each consists of an extracellular signal peptide-binding region composed of three
immunoglobulin-like domains and a series of acidic amino acid residues (termed the acid
box) and cytoplasmic tyrosine kinase domains linked by a hydrophobic transmembrane
domain (Coutts & Gallagher, 1995). Receptors can be activated by a several FGFs and a
single FGF may bind to several different receptors, though FGFRs differ from one
another in their ligand affinity and tissue distribution (Omitz, et al., 1996). Acting via
FGFRs, of which all four are expressed in hES colonies (Stewart, et al., 2008), bFGF is
an important regulator of hES cell proliferation (Levenstein, et al., 2006) and has a role as
a potent mitogen in fibroblast populations (Omitz & Itoh, 2001). All of these various
mechanisms help bFGF to promote the maintenance of the undifferentiated state in hES
cells and other stem cells types.
Not all cells, even within a clonal cell population, have the ability to respond to
bFGF signals (Bendall, et al., 2007). bFGF and IGF (an important support factor for hES
cells) each act on distinct cell populations which exclusively express receptors for only
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one of these growth factors. Only cells that express the IGF receptor have the capacity to
generate new colonies of hES cells, whereas the cells responding to bFGF are a sub
population of fibroblast-like cells known to arise spontaneously at the periphery of hES
cell colonies. These fibroblast-like cells are critical in supplying the hES cells with the
signals necessary to proliferate and self-renew (Bendall, et al., 2007). With adult stem
cells, which typically grow in a monolayer instead of colonies, there is also an important
bFGF-IGF collaboration. IGFs induce autocrine and paracrine effects on stem cells and
consequently bFGF-mediated release of IGFs may lead to the upregulation of FGFR and
IGFR expression in neighbouring cells. This synergistic-positive feedback mechanism
leads to the proliferation of mesenchymal stem cells derived from human umbilical cord
blood (S. B. Park, et al., 2009).

1.3.6 Limitations associated with the use o f hES cells fo r regenerative medicine
While the enormous potential for hES cells remains under constant focus in the
scientific community, and despite pioneering use in clinical trials (Trounson, et al.,
2011), there are still a number of hurdles to be overcome before their widespread use in
patients. These limitations include ethical, biological and technical hurdles. Ethical
dilemmas are among the most controversial aspects of embryonic stem cell research. The
most cited criticism of the derivation of human embryonic stem cells is the destruction of
the human embryo while harvesting the ICM to create embryonic stem cell lines. This
argument stems from the debated moral status of the embryo on ethical and religious
grounds (Walia, et al., 2011), which has created a situation of restricted funding for hES
cell research in many nations including the United States of America (Annas, 2011;
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Cohen & Adashi, 2011). The allotransplantation of cells has similar immunological
incompatibility problems as organ transplant, namely the risk of rejection by the
transplant recipient, a significant barrier for their clinical application. hES cells used in
regenerative therapies are derived from tissue that is genetically different than the patient.
To overcome this issue, methods such as somatic cell nuclear transfer were used to
generate human embryos (J. Li, et al., 2009) and primate ES cells (Byrne, et al., 2007).
hES-like cells have also been derived by fusing somatic cells with cells from established
ES cell lines (Cowan, et al., 2005; Wilmut, et al., 2002). These methods, however, have
also been impeded due to ethical complications, acutely low efficiencies, genetic
abnormalities (Tada, et al., 2001; Ying, et al., 2002; J. Yu, et al., 2006) and the minimal
availability o f human egg source material (Walia, et al., 2011). Apart from immunoincompatibility issues, there is also a concern of genetic abnormalities accumulating over
the long-term maintenance of hES cells. Among these karyotypic anomalies accrued are
trisomy and aneuploidy (Oh & Choo, 2006). The enzymatic passaging common with
several hES cell lines is one element that may increase the instance of these genetic
instances (Buzzard, et al., 2004; Mitalipova, et al., 2005). Irrelevant of the cause(s) of
karyotypic variation, it is clear that genomic analyses must be routinely conducted in
expanded hES cell cultures intended for clinical application to detect the accumulation of
genetic mutations, which are associated with carcinogenesis (Leedham, et al., 2005).
Traditionally hES cells have been cultured on MEFs, which raises concerns of
xenosis, an infection of agents such as bacteria or viruses that are derived from animals.
These can be from direct transplantation of infected tissues, cells or organs or infections
derived from culture conditions (Fishman, 1997). These diseases not only pose risk to the
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patient but potentially to the general population. A step towards the elimination of these
risks was the expansion and maintenance of hES cell cultures on human fibroblasts
derived from newborn human foreskin (A. B. Choo, et al., 2004) and use of these cells
with an artificial protein matrix and MEF-conditioned media. To maintain the
pluripotency of hES cells fully defined culture conditions are necessary with an
established amount of known factors (Oh & Choo, 2006). Serum- and feeder-free culture
has recently become a reality (Y. Li, et al., 2005b) and is now commercially available
with established protocols (Hannoun, et al., 2010; S. Lin & Talbot, 2011). These systems
do not seem to have an effect on the immortal and pluripotent state or differentiative
capacity of stem cells, as reported by Hannoun et al (2010), though more investigation is
needed before these systems can be used to generate cells for clinical applications.

1.4 Induced Pluripotent Stem (iPS) Cells
1.4.1 Viral Reprogramming
With significant ethical, biological and technical obstacles to the progression of
hES cells from the bench to the clinic, in 2006 Shinya Yamanaka created the first iPS
cells by retrovirally introducing four transgenes that encoded the transcription factors
Oct3/4, SOX2, KLF4 and c-Myc into mouse fibroblasts (Takahashi & Yamanaka, 2006).
These first generation iPS cells were similar to ES cells in their proliferative and
differentiative capacity and demonstrated similar morphology and expression of
pluripotency markers, including SOX2, OCT4, KLF4, and Nanog. The creation of human
iPS cell lines quickly followed in 2007 from two independent groups: Yamanaka, using
the previous complement of transcription factors in a retroviral system (Takahashi, et al.,
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2007), and James Thomson using a lentiviral system and a different set of factors
including SOX2, OCT4, Nanog and LIN28 (J. Yu, et al., 2007) (Figure 1.4). Both the
viral delivery methods (transfection systems that insert transgenes into the host’s genome
randomly) and select pluripotency genes themselves (namely c-myc, a known proto
oncogene) have presented obstacles to the safety of iPS cells as resultant cell lines could
exhibit tumorigenicity. Numerous advances, such as the use of non-integrating
adenoviruses, used recently in both mouse (Stadtfeld, et al., 2008) and human fibroblasts
to successfully generate iPS cell lines successfully (Zhou & Freed, 2009) aim to address
such barriers to their clinical application.

1.4.2 Current limitations with iPS technology
iPS cells share many characteristics of ES cells, including some of their hurdles to
therapeutic applications, however because they could be made from a patient’s somatic
cells, iPS cells are virtually free from ethical dilemma and have a largely reduced risk of
rejection as compared to hES cells. Issues of iPS cells include tumorigenicity, genomic
and epigenomic abnormalities, and cellular memory retention from origin tissue
(Barrilleaux & Knoepfler, 2011; Martins-Taylor & Xu, 2011; Okita, 2010).
As compared to the derivatives of ES cells, anomalous gene expression in iPSderived cells can induce the T-cell-dependent immune response normally seen in organ
rejection in synergistic recipients (T. Zhao, et al., 2011). The response was, however,
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A.

B.

Figure 1.4 Retroviral and Lentiviral reprogramming strategies. A. Reprogramming
factors are individually packaged in retroviruses and used to infect somatic cells where
they randomly and stably integrate into the host genome. There may be a disproportionate
number of copies in each nucleus and multiple viral integrations are necessary. B.
Reprogramming factors can also be packaged together into a single lentiviral vector,
where they are expressed from a single transgene, infecting cells with fewer integrations
and proportional copy number. Both systems result in permanent transgene genomic
integration and random integration that could create genetic abnormalities.
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more severe with cells reprogrammed by viral means in comparison to iPS cells
reprogrammed using an episomal vector method. It must also be noted that the authors
used undifferentiated iPS cells, unlikely to be used in a clinical setting, as iPS, as well as
ES cells, are known to form teratomas (Apostolou & Hochedlinger, 2011). It has been
suggested that the reprogramming process introduces atypical epigenetic as well as
genetic anomalies, a likely cause of abnormal gene-expression patterns (Wu &
Hochedlinger, 2011). This study also indicates that the genetic abnormalities can
accumulate and amplify presenting a danger of tumorigenicity, especially when
mutations occur in areas comprising cancer-associated genes. It has also been reported
that low-passage iPS cells generated by various means and derived from adult tissues
representative of the three embryonic germ layers (hepatocytes, dermal fibroblasts and
melanocytes) retain a transcriptional memory of their tissue of origin. The expression of
genes reflecting the tissue of origin tend to regress at later passages, which suggests that
they are progressively silenced during reprogramming and do not constitute a permanent
and distinguishable iPS signature (Chin, et al., 2009; Polo, et al., 2010). It has also been
determined that incomplete promoter DNA methylation can explain some of the enduring
expression of somatic genes (Ohi, et ah, 2011). This characteristic of iPS cells has now
been reported to persist into later passages and to correlate with defects in the re
establishment of DNA methylation caused by both selective pressure and genomic
environment (Barrero & Izpisua Belmonte, 2011).
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I. 4.3 Alternative methods o f reprogramming
The notion that transgene integration was not necessary for the induction of
pluripotency, led to the development of many other techniques to create iPS cells lines
including use of the piggyBuc transposon system (Woltjen, et al., 2009), site specific
recombination methods using the cre-loxP system (Chang, et al., 2009; Sommer, et al.,
2010), non-integrating episomal vectors (Okita, et al., 2010; Stadtfeld, et al., 2008; J. Yu,
et al., 2009), and synthetic RNAs (Plews, et al., 2010; Warren, et al., 2010). All these
methods, whether integrating or not, involve transfection of exogenous genetic
instructions into the cell.
Recently a movement has been made towards the generation of iPS cells by
means of small molecule-induced epigenetic manipulation and chromatin remodeling to
regulate the transcription of endogenous pluripotency factors (Strahl, et al., 1999). Small
molecules including VP A, SAH, and the growth factor bFGF, a critical component of the
in vitro hES cell microenvironment, have been shown to dramatically improve
reprogramming efficiency. VPA is commonly used to facilitate cellular reprogramming
for iPSC generation (Debeb, et al., 2010; Huangfu, et al., 2008a; Medvedev, et al., 2011;
Plews, et al., 2010) by interfering with the function of FtDACs, causing uncoiling of the
histone and allowing gene expression. SAH has been shown to promote epigenetic
modification during somatic cell nuclear transfer (Jeon, et al., 2008) via negative
feedback inhibition of DNA methyltransferase (DNMT)-mediated DNA methylation (W.
J. Lee, et al., 2005). bFGF has been shown to help induce stem cell specific gene
expression in somatic cells (Page, et al., 2009). Page et al (2009) demonstrated the ability
to induce the endogenous expression of pluripotency factors in human dermal fibroblasts
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(hDFs) using bFGF supplementation and culture of cells under hypoxic conditions.
Hypoxia has been shown to aid in maintaining pluripotency of both mouse and human ES
cells (Forristal, et al., 2010; Millman, et al., 2009; Zachar, et al., 2010) and even to
enhance the generation of human iPS cells (Yoshida, et al., 2009). Small molecule
treatments have enhanced the reprogramming efficiency and have reduced the number of
exogenous transcription factors requiring only OCT4 and SOX2 for pluripotency
induction (Huangfu, et al., 2008b).
From the first retroviral reprogramming (Takahashi & Yamanaka, 2006), to
reprogramming with traceless excision of transgenes using the piggyBac transposon
(Woltjen, et al., 2009; Yusa, et al., 2009), to DNA construct-ffee mRNA transfection
(Plews, et al., 2010), the trend in iPS technology has been towards the derivation of
‘footprint-free’ human iPS cells. These cells have been successfully generated from skin
fibroblasts, adipose tissue-derived cells, and cord blood using a small molecule cocktail
which included MEK inhibitor PD0325901, GSK3(3 inhibitor CHRI99021, TGFp/Activin/Nodal receptor inhibitor A-83-01, ROCK inhibitor, HA-100 and human
leukemia inhibitory factor (T. Lin, et al., 2009; J. Yu, et al., 2011a). Feeder-free
reprogramming conditions have been also been established with the help of small
molecules, bFGF and N2B27 (StemCell), and the chemically defined hES cell medium
mTeSRl for the derivation of iPS cells without the use of exogenous DNA (J. Yu, et al.,
2011a).
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1.5 Cell types used in human cell reprogramming
1.5.1 Human dermal fibroblasts
hDFs are the most common source for reprogramming cells into iPS lines due to
their accessibility and the established and extensive banking systems (Bosco, et al.,
2011). hDFs are cells derived from either the adult dermis or neonatal foreskin.
Fibroblasts are found universally in connective tissues, and can synthesize and secrete
extracellular matrix proteins under cell culture conditions (Hedman, et al., 1979).

1.5.2 Other cell types in reprogramming
Another route that has been taken to achieve induced pluripotency with as few
factors as possible, is the choice of cell type to reprogram. Sourced from neonatal
foreskin, keratinocytes provide a 100-fold more efficient reprogramming source than
fibroblasts (Aasen, et al., 2008). These studies reported the generation of keratinocytederived iPS cells from a single human hair. Melanocytes have also been used as a source
material for reprogramming, providing a higher efficiency and requiring fewer factors
(Utikal, et al., 2009). Outside of the dermal sphere, researchers have also looked to an
underutilized and abundant source of human tissue for reprogramming. From liposuction
patients, adipose tissue was processed to isolate fat tissue stem cells, yielding numbers,
which would require extensive culture o f fibroblast biopsies to equal (N. Sun, et al.,
2009). These cells can also be readily cultured within feeder-free conditions and take
about a third o f the time to reprogram than dermal fibroblasts.
Adult stem cells endogenously express some of the pluripotency genes and are
generally less differentiated populations found in the body, such as neural stem cells
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(Kim, et al., 2009) and stem cells from umbilical cord blood (Baal, et al., 2004; C.
McGuckin, et al., 2008; C. P. McGuckin & Forraz, 2008; Reed & Johnson, 2008; B. Sun,
et al., 2007; Y. Zhao, et al., 2006). Kim et al (2009) created “one-factor” iPS cells using
adult mouse neural stem cells with exogenous expression of OCT4. Umbilical cord blood
stem cells are the intermediate point between embryonic/fetal and adult life and have
longer telomeres per chromosome and high cell proliferation potential, attributes not
common in somatic cells. Umbilical cord blood (UCB) is an attractive source material for
iPS cell production because it is easily accessible at the time of birth with minimal
invasiveness and is a very rich source of immunologically naive stem cells. iPS cell lines
have successfully been generated from umbilical cord-derived cells with a high efficiency
in several cases (Giorgetti, et al., 2010; Haase, et al., 2009; K. Hu, et al., 2011; C.
McGuckin, et al., 2008)

1.5.3 Human multi-lineage progenitor cells
Human multi-lineage progenitor cells (hMLPCs) are a mesenchymal-like
multipotent stem cell line isolated from post-partum human UCB with fibroblast-like
morphology (Bio E, Inc., personal communication). These cells are a subtype of UCB
stem cells and express cell surface antigens CD34, CD45, CD9, SSEA-3, SSEA-4,
STRO-1, SCF, and CD133 (Dr. Dan Collins, BioE Inc., unpublished data) upon
derivation from human UCB as leukocyte cells and were subsequently differentiated into
fibroblast-like cells before expansion into a clonal subpopulation. These cells loose the
markers CD34, CD45, SSEA-3, SSEA-4, STRO-1, SCF and CD 133 but can still
differentiate into all three germ layers (Berger, et al., 2006; C. McGuckin, et al., 2008).
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Various cell lines have been derived from umbilical cord blood and shown to express the
OCT4, SOX2 and Rexl transcription factors among other embryonic genes, hallmarks of
a less differentiated cell type (Baal, et al., 2004). Grown in an adherent monolayer culture
system, hMLPCs are easy to maintain and expand in vitro.

1.6 Rationale
To be clinically applicable, iPS cell technology must become safer and more
efficient. The need for extrinsic factor integration, as well as non-integrating
reprogramming techniques involving exogenous DNA has been eliminated with reports
o f footprint-free reprogramming using small molecules as instruments for epigenetic
modifications to the genome (J. Yu, et al., 201 la). As differentiation advances, chromatin
changes to a repressed and inactive state (Shafa, et al., 2010), therefore reversing this
process is critical for the induction of pluripotency. DNA methylation inhibitors are
known to increase the efficiency of reprogramming through expanding chromatin,
allowing the transcription of previous silenced genes (Gaspar-Maia, et al., 2011).
Reprogramming cell types that endogenously express critical pluripotency factors or exist
in a progenitor state has been shown to increase the efficiency and efficacy of iPS cell
reprogramming (Kim, et al., 2009; Pasha, et al., 2011). Access to adult progenitor cells
can be difficult or dangerous to the patient, however umbilical cord blood-derived
progenitor cells are a rich source, easily accessed at the time of birth. Banking of cord
blood is becoming increasingly common, providing a future long-term source of these
cells

for

reprogramming

material.

Furthermore,

UCB-derived

stem

cells

are

immunologically naive and therefore are less likely to be rejected, in contrast to
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mature/fully differentiated cells which have been shown to trigger immune responses
when reprogrammed (T. Zhao, et al., 2011).

1.7 Hypothesis
Valproic acid and s-adenosylhomocysteine will increase pluripotency factor levels in
human multi-lineage progenitor cells (hMLPC) in the presence of basic fibroblast growth
factor.

1.8 Objectives

1) To determine the presence of the FGFR family to ensure that cells are competent to
respond to basic fibroblast growth factor and to define baseline levels of pluripotency
factors in hMLPCs.
2) To determine the effect of global DNA demethylation and histone acetylation on
pluripotency marker expression.
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CHAPTER TWO: MATERIALS AND METHODS

2.1 Cell Culture
Human multi-lineage progenitor cells (hMLPCs), a clonal cell population of
karyotypically normal, multipotent progenitor cells isolated from post-partum human
umbilical cord blood, were obtained from BioE (BioeE Inc., St. Paul MN. USA).
hMLPCs were cultured in mesenchymal stem cell growth medium (a kit containing
mesenchymal stem cell basal media, L-glutamine, antibiotic, and serum; Lonza) on either
140 mm culture dishes (NUNC) or 10 cm culture dishes (CellStar). Cells were passaged
enzymatically at approximately 60% confluency with 0.25% Trypsin-EDTA (Lonza) and
were re-seeded at approximately 1,500 cells/cm2. Media was changed by complete
replacement every 3 days.
Human dermal fibroblasts (hDFs) isolated from adult skin were obtained from
Invitrogen. hDFs were cultured in medium consisting of DMEM (GIBCO) supplemented
with 10% fetal bovine serum (GIBCO), 1% Penicillin Streptomycin solution (Lonza), and
1% Glutamax (GIBCO), on 10 cm culture dishes (CellStar). Following enzymatic
passaging at approximately 95% confluency with 0.25% Trypsin-EDTA (GIBCO), cells
were seeded at approximately 635 cells/cm2 and media was changed by complete
replacement every 3 days.
Human embryonic stem (hES) cell lines CA2 (Seguin, et al., 2008) (Courtesy of
Dr. Cheryle Séguin, UWO) and H9 (Amit, et al., 2000)(Courtesy of Dr. Lynne Postovit,
UWO), positive controls for the expression of pluripotency factors, were maintained on
mitotically inactivated mouse embryonic fibroblasts (MEFs) or on Geltrex (GIBCO) with
MEF-conditioned media. Knockout DMEM (GIBCO) supplemented with 10% serum
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replacement (GIBCO), 1% Penicillin Streptomycin solution, 1% GlutaMAX (GIBCO),
1% lOOx non-essential amino acid (NEAA; GIBCO), 20 ng/ml bFGF (Invitrogen) and
0.1 pM 2-mercaptoethanol (GIBCO) was used to maintain cultures and was changed
daily. Cells were expanded via enzymatic passaging with 0.05% Trypsin-EDTA
(GIBCO) and plated at a 1:6 ratio when the majority of colonies were flattened and
mature to keep hES cells replicating in a pluripotent state. H9 hES cells were maintained
with F-12 Knockout DMEM basal media (GIBCO) supplemented with 20% Knockout
Serum Replacement Serum, 0.08% L-glutamine (Cellgro), 0.01% NEAA, 4ng/ml bFGF,
and 0.1

pM

2-mercaptoethanol (Fisher Scientific). Mature H9 colonies were

mechanically passaged into matrigel-coated dishes.

2.2 Mouse embryonic fibroblasts
MEFs (Stem Cell Facility, Hospital for Sick Children) were expanded on 0.1%
gelatin (BioShop) coated 14 cm cell culture dishes and irradiated at 8000 rads. Cells were
then cryopreserved at -80°C for storage and then plated on gelatin-coated plates at 52,000
cells/cm2 as a substrate for embryonic stem cell culture or for the generation of MEFconditioned media.

2.3 Small Molecule and growth factor treatments
hMLPCs and hDF cells were treated with 20 ng/ml bFGF, 1 mM valproic (VPA,
Sigma-Aldrich) and 0.5 mM s-adenosylhomocysteine (SAH, Sigma-Aldrich), bFGF and
VP A, bFGF and SAH, and the combined treatment of bFGF, VPA and SAH (Figure 2.1).
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A crystalline VPA sodium salt (Sigma-Aldrich) was dissolved to a 1M solution in
Dulbecco's Phosphate-Buffered Saline (DPBS, GIBCO) and stored at -20°C. A 3mM
stock was created by diluting the 1M solution into cell culture media. The 3 mM VPAmedia was filtered through a 0.2 pM filter (Nalgene) and used, with other stock media, to
create treatment medias.
A 2.6 mM SAH stock solution was created from dissolving crystalline SAH at 1
mg/ml in cell culture media and stored at -20°C. This 3X stock was filtered and used to
create treatment medias.
A 20 pg/ml bFGF solution was diluted to a stock of 60 ng/ml in either hDF or
hMLPC cell culture media. This 3X stock was filtered and combined with other stock
medias and non-supplemented media to create treatment media combinations.

2.4 Cell Counting
Using the Accuri C6 flow cytometer (BD Biosciences), hDF and hMLPC
suspensions were counted to ensure accurate and consistent seeding densities. Cell
number was likewise quantified throughout and following treatments to track potential
changes in cell number. 100 pi samples of cell suspensions (equivalent to 1/50 of cells)
were taken and diluted 10-fold and cell numbers were extrapolated from these counts.
The number of population doublings were calculated with the formula: 3.32*log(final cell
count /initial cell count).
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Figure 2.1 Cell Treatment. hMLPC and hDF cells were treated for 7 days with media
supplementation of each VPA, SAH, bFGF, bFGF+VPA, bFGF+SAH, and
bFGF+VPA+SAH, using the untreated cell types as a baseline reading for various
experiments and hES cells as the positive control for the pluripotency factors. Cells were
plated at day 0 (DO), treated from days 1-4, passaged on day 4 (D4) where treatment
continued until cell collection on day 7 (D7).

2.5 Immunocytochemistry
hDFs and hMLPCs were enzymatically passaged and plated into 4-well Lab-Tek
glass chamber slides (NUNC) at 635 cells/cm and 1500 cells/cm‘ respectively. hES cells
were mechanically passaged into Geltrex-coated chamber slides. After 7-day treatment of
hMLPCs/hDFs and maturation of hES colonies, cells were rinsed twice with phosphatebuffered saline (PBS) and fixed with 4% paraformaldehyde in PBS for 15 minutes at
room temperature (RT) and again rinsed twice with PBS. Cells were then blocked in
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phosphate-buffered saline-Triton X-100 (PBST, (0.1% Triton X-100 [EMD] in PBS) and
5% goat serum (GS, Sigma-Aldrich) for one hour at RT. All antibodies were diluted in
PBST/GS and incubated for one hour at RT and 0.5 pg/ml Hoescht 33342 nuclear stain
(Crissman & Steinkamp, 1987) was added with the secondary antibody solution. Cells
were rinsed twice with PBST between incubations. Antibodies and respective
concentration are as follows: 0.5 pg/ml anti-SOX2 (H-65, Santa Cruz), 0.5 pg/ml antiOCT3/4 (C-10, Santa Cruz), 0.4 ug/ml anti-KLF4 (H-180, Santa Cruz), 0.4 ug/ml antiNanog (ReproCELL), 0.78 pg/ml anti-FGFRl (VBS1, Millipore), anti-1 ug/ml FGFR2
(C-17, Santa Cruz), 1 pg/ml anti-FGFR3 (C-15, Santa Cruz), and 0.5 pg/ml anti-FGFR4
(C-16, Santa Cruz). Cell images were captured using a Leica DMI6000 B inverted
microscope and ORCA-R2 digital camera (C l0600, Hammumatsu). Exposure and image
acquisition times remained constant between all cell types and treatments for each
primary antibody target but not between target types. Where there was variability in the
expression of pluripotency factors, cells counts were performed to determine the
proportion of cells which expressed the pluripotency proteins.

2.6 Western Blotting
Whole cell protein extracts were obtained from cell pellets lysed with
radioimmunoprécipitation assay (RIPA) buffer (50mM Tris-HCL pH 7.4, 1% NP-40,
0.25% Na-deoxycholate, 150mM NaCl) and complete mini protease inhibitor (Roche).
Protein concentrations were established using a RC DC™ protein assay (BioRad) using a
BSA 5 point standard curve from 2 mg/ml to 0.125 mg/ml, quantified by the Spectramax
spectrophotometer (Molecular Devices). Protein was loaded (30 pg for FGFRs and 10 pg
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for pluripotency factors) into a precast 4-12% Bis-Tris gradient gel (NuPage) for smaller
proteins (e.g. pluripotency factors), while 7.5% Bis-Tris gels were utilized for immunoblotting larger receptor proteins. Detection was accomplished with horse radish
peroxidase (HRP)-linked antibodies (Cell Signaling) and chemiluminescence induced by
ECL substrate (SuperSignal, ThermoScientific). Anti-(3-actin (Sigma) was used as a
loading control. Image Lab was used to conduct densitometry on FGFR immunoblots to
ensure that levels detected in the various cell types were consistent with patterns in
immunocytochemistry.

2.7 Quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was extracted from cell pellets using Trizol reagent (Invitrogen)
according to the manufacturers instructions. The RNA yield was determined using a
NanoDrop 2000 (Thermo Scientific) and RNA quality was measured by means of the
A260/A280 ratio. Samples were subsequently run on a 1.5% agarose-0.4% formaldehyde
gel containing ethidium bromide to validate RNA integrity by visualization of the ratio of
the 28S:18S bands and to screen for any degradation (Figure S-l). 0.5 micrograms of
RNA from each sample was used to synthesize cDNA using the ¿Script cDNA Synthesis
Kit (BioRad Laboratories), which was a combination of oligo(dT) and random hexamer
primers. Samples were incubated for 5 minutes at 25°C, 30 minutes at 42°C, and 5
minutes at 85°C, according to the iScript reaction protocol using a CFX96 Thermocycler
(BioRad Laboratories) and then stored at -20°C. SsoFast Evergreen Supermix (Bio-Rad)
was used for detection of PCR products and quantified using the BioRad CFX384 RealTime PCR Detection System. In each PCR reaction, a total volume of 8 pi comprised of
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1/15 diluted cDNA (1 ¡llI), and master mix containing 4 ul SsoFast master mix (dNTPs,
EvaGreen dye and SsoFast fusion polymerase) and RNase/DNase-free water. Primer sets
specific to human pluripotency factors OCT4, SOC2, KLF4, Nanog and Cyclophilin G
(CYCG) a housekeeping gene for data normalization, were utilized (Table 2.1). Primer
sets specific for OCT4, SOX2 and Nanog were previously validated (Seguin, et al.,
2008). The KLF4 primer sequences were obtained from published reports and validated
by our group (Rashid, et al., 2010). A 5-fold dilution series of cDNA from hES cells was
used to create a four-point standard curve in order to assess the efficiency of the KLF4
primer pair (Figure S-2). RT-PCR reactions were carried out using the BioRad CFX384
thermocycler using the following protocol: 95°C for 2 minutes, then 95°C for 10 seconds
and 60°C for a 39-cycle loop followed by incubation at 65°C for 5 seconds. Subsequent
to amplification, a melt curve was generated for temperatures between 65°C and 95°C to
determine the specificity of primers (Figure S-3). Relative fold changes in pluripotency
genes were calculated using the comparative cycle times (Ct) method expressed with
reference to CYCG as the reference gene and normalized to human embryonic stem cells
AACt

or untreated cell types using the formula 2

Table 2.1: Primer sequences used in Quantitative reverse transcription-PCR (qRT
PCR)
G en e

F o r w a r d S e q u e n c e ( 5 ’ to 3 ’)

R e v e r s e S e q u e n c e ( 5 ’ to 3 ’)

D e ta ils

CYCG

C TTG TC A A TG G CCA A C A G A G G
TG A TTTG TG G G C CTG A A G A A A
TG G G C TCG A G A A G G A TG TG
TA CA G CA TG TC CTA CTC G C A G
G A TG A A C TG A CC A G G CA CTA

GCCCA TCTA A A TG A G G A G TTG G T
G A G G CA TCTC A G CA G A A G A CA
G C A TA G TC G C TG C TTG A TCG
G A G G A A G A G G T A A CC AC AGGG
GTG G G TCA TA TCCA CTG TCT

housekeeping
gene
pluripotency
pluripotency
pluripotency
pluripotency

N anog
O c t3 /4
Sox2
KLF4
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2.8 Global DNA methylation quantification
To assess the optimal dose for SAH treatment, global DNA methylation was
quantified after a 7-day dose response comprised of 0 mM, 0.25 mM, 0.5 mM, 2 mM and
4 mM SAH media supplementation by means of the Imprint Methylated DNA
Quantification Kit (Sigma-Aldrich) according to the manufactures instructions. DNA was
extracted using the GenElute Mammalian Genomic DNA Miniprep Kit (G1N70, SigmaAldrich) and quantity and purity were determined with the NanoDrop 2000 (Thermo
Scientific). Sample genomic DNA and a standard curve of 200, 100, 50, 25 and 0 ng/ul
methylated DNA were bound to assay plate walls and blocked before kit-provided
capture and detection antibodies were added. The colour-metric reaction determining
methylation was quantified with Spectramax spectrophotometer (Molecular Devices) at
450 nm.

2.9 Statistical analysis

GraphPad Prism 5a software was used to conduct one-way ANOVA analysis,
comparing SAH-induced methylation and for cell counts, population doublings, and
mRNA expression differences between cell types and between experimental treatments.
Tukey’s post-hoc test was performed to determine statistically significant differences in
data analyzed by one-way ANOVA. All data is presented as mean ± SEM. Statistically
significant data was set at a p-value of 0.05 or less.
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CHAPTER THREE: RESULTS
3.1 Effects of small molecule and growth factor treatment on hDF and hMLPC cell
number and morphology
3.1.1 The effect o f bFGF on the morphology o f hDFs and hMLPCs
To observe possible morphological effects that bFGF may have on hDF and
hMLPCs, cells were maintained in culture media supplemented with 20 ng/ml bFGF for 7
days. bFGF-treated hDFs showed a more elongated spindle-like shape (Figure 3.1),
which is congruent with past publications (Page, et al., 2009). hMLPCs appear to have a
more variable morphology, some quite elongated, others very compact and rounded with
or without extensions. Cells did not assume any one consistent morphology upon
treatment with bFGF.

3.1.2 The effect o f VPA on cell number and morphology
hDF and hMLPC culture media was supplemented with the histone deacetylase
inhibitor valproic acid for 7 days in a dose response study using concentrations of 0 mM,
0.25 mM, 0.5 mM, 1 mM and 2 mM. The selected concentrations were based on previous
studies, which employed a dose of 1 mM (Huangfu, et al., 2008a; Huangfu, et al., 2008b;
Medvedev, et al., 2011). Initially the dose response included 4 mM but this was shown to
be largely detrimental causing rapid cellular senescence, in which cells lose their ability
to divide. This is marked by enlarged and flattened cellular morphology (Figure S-4).
Cell counts after 7 days of treatment revealed an inversely proportional relationship
between hDF and hMLPC cell density and VPA concentration (Figure 3.2). hDFs were
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negatively affected by 0.5 mM VPA treatment, which caused a 25% decrease in cell
population. In both hDFs and hMLPCs, VPA had a more robust detrimental effect on cell

hDF

hMLPC

untreated

bFGF

Figure 3.1 Influence of bFGF on cell morphology in hDFs and hMLPCs. hDF and
hMLPCs were maintained in culture media supplemented with 20ng/ml bFGF for 7 days
then visualized to asses potential influences on cell morphology. hDF treated with bFGF
showed a more elongated spindle-like shape, indicated by arrows. hMLPCs appear to
have a more variable morphology that was not largely affected by bFGF treatment. Scale
bars are equal to 200 pm. Images are representative. (n=3).
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numbers at 1 mM, showing a 50% and 70% population decrease respectively. This effect
further increased at a concentration of 2 mM, with an 80% and 95% decrease in the
number of cell respectively, accompanied by the appearance of an enlarged and flattened
senescent-like morphology in hDFs (Figure 3.3). hMLPC morphology did not appear to
be affected by VP A treatment (Figure 3.4). Although some effects were on cell viability
at 1 mM VPA it is the typical concentration utilized previously in direct cell
reprogramming experiments (Hezroni, et al., 2011; Huangfu, et al., 2008b; X. N. Li, et
al., 2005a), and so to increase the probability of VPA effects on the cells a treatment of 1
mM VPA was used in all subsequent experiments.

3.1.3 The influence o f SAH on global DNA methylation in hMLPCs
hMLPC cells were treated with increasing concentrations of the DNAmethylation inhibitor SAH (0 mM, 0.25 mM, 0.5 mM, 1 mM and 2 mM) supplemented
into mesenchymal stem cells media for 7 days. SAH did not appear to influence cell
morphology (Figure 3.5). Higher concentrations of 2 mM and 4 mM appeared to decrease
cell number by approximately 25% and 40% respectively over untreated controls (Figure
3.6). DNA was isolated for global DNA methylation analysis, which revealed a decrease
in global DNA methylation with increasing SAH concentration (Figure 3.7). There was a
65% decrease in DNA methylation in 0.5 mM treated hMLPCs as compared with
untreated cells, which also correlated with a marked increase in the cell number of almost
20% (Figure 3.6). Decreased DNA methylation was also present in 1 mM samples.
However, since the greatest inhibition of DNA methylation was observed at 0.5 mM, this
concentration was used in subsequent experiments.
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Figure 3.2 The effects of VPA on hDF and MLPC cell numbers. hDF and hMLPC
cells, seeded at 635 cells/cm2 and 1,500 cells/cm2 respectively, were treated with VPA in
a dose response of 0 mM, 0.25 mM, 0.5 mM, 1 mM and 2 mM for 7 days. Cells were
then collected and counted to determine effect of VPA concentration on cell numbers.
There appears to be an inversely proportional relationship between hDF and hMLPC cell
counts and VPA concentration. Significantly decreased cell populations are seen in 0.5
mM, 1 mM, and 2 mM treated hDFs and 1 mM and 2 mM treated hMLPCs from 0 mM
controls. The decrease in cell population between 0.5 mM was not significantly different
from 1 mM in hMLPCs. Data is presented as mean ±SEM. Significance indicated by *, p
< 0.05. (n=3).
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Figure 3.3 The effects of VPA on hDF morphology. Cultures were seeded at an initial
density of 635 cells/cm2 (day 0) and on day 1 culture media was supplemented with
valproic acid that was maintained for a total of 7 days at concentrations of 0.25 mM, 0.5
mM, 1 mM and 2 mM with non-supplemented media used as a control. Media was
changed daily. Valproic acid appeared to affect cell confluency at 1 mM and at 2 mM
induced the more frequent appearance of a senescent morphology indicated by arrows.
Scale bars are equal to 200 pm. (n=3).
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Figure 3.4 The effects of VPA on hMLPC morphology. Cultures were initially seeded
at a density of 1,500 cells/cm2 (day 0) and on day 1 culture media was supplemented with
valproic acid at concentrations of 0.25 mM, 0.5 mM, 1 mM and 2 mM, with
unsupplemented media used as a control. Media was changed daily and cells were
maintained for 7 days. Valproic acid appears to decrease cell confluency at ImM with
more robust decreases observed at 2 mM. Scale bars are equal to 200 jrm. (n=3).

42

OmM

0.25mM

0.5mM

1.0mM

2mM

4mM

Figure 3.5. SAH effects on hMLPC morphology. SAH culture media supplementation
at concentrations of 0.25 mM, 0.5 mM, 1 mM, 2 mM or 4mM for 7 days does not appear
to have an observable effect on the morphology of hMLPCs. Scale bars are equal to 200
pm. (n=l).
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Figure 3.6. SAH effects on hMLPC cell numbers. hMLPC cells were treated with SAH
via media supplementation in a dose response of 0 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM
and 4 mM for 7 days and then collected and counted to determine potential effect on cell
numbers. At doses of 2 mM and 4 mM there appears to be a detrimental effect on
hMLPC numbers. The cell population treated with 0.5 mM SAH appears to have an
increase in numbers as compared to untreated control populations. (n=l).
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Figure 3.7. The effects of SAH on DNA methylation levels in hMLPCs. hMLPC cells
were treated with SAH (Sigma Aldrich) via mesenchymal stem cell culture media
(MSCGM Bulletkit, Lonza) supplementation in a dose response of 0 mM, 0.25 mM, 0.5
mM, 1 mM, 2 mM and 4 mM for 7 days, passaged on day 4, before collection and DNA
isolation using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich).
Global DNA methylation levels were quantified using the Imprint Methylated DNA
Quantification Kit (Sigma-Aldrich), which is based on an HRP-linked antibody
colorimetric reaction quantified with a spectrophotometer. SAH concentrations of 0.5
mM and 1 mM resulted in lower DNA methylation levels compared to untreated
hMLPCs. 0.5mM SAH treatment resulted in a 65% decrease in global DNA methylation.
Data is presented as mean ±SEM, from technical replicates. (n=l, technical replicates =3)
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Figure 3.8. Validation of FGFR antibodies by western blotting. Gel electrophoresis
reveals the correct size of proteins immuno-detected by FGFR primary antibodies,
confirming antibody specificity in the immunocytochemistry experiments. 30 pg of
protein were loaded into 7.5% Bis-Tris gels and separated by protein size via
electrophoresis. Anti-FGFRl antibody (Millipore) and anti-FGFRs 2, 3 and 4 (Santa
Cruz) were used to immuno-detect the receptors in cell lysates of hES cells, hMLPCs and
hDFs. Detection was accomplished with HRP-linked secondary antibodies (Cell
Signaling) and chemiluminescence induced by ECL substrate (SuperSignal,
ThermoScientific). Anti-P-actin (Sigma) was used as a loading control between samples.
Receptors were all detected in each cell type within the range of the expected size for all
FGF receptor proteins. Densitometry was performed to normalize detection levels in
order to compare levels relatively. Levels of FGFR 1 and 3 were comparable between
hESCs and hMLPCs. hMLPCs had the highest detection of FGFR2. hDFs were
consistently lower in FGFRs compared to other cells types. (n=l)
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3.2 Influence of small molecule and growth factor treatments on hDF and hMLPC
cell proliferation
hDFs and hMLPCs were treated with 20 ng/mL bFGF, 1 mM VP A, 0.5 mM
SAH, individually and at the same concentrations in combinations of bFGF+VPA,
bFGF+SAH or bFGF+VPA+SAH for 7 days, via supplementation into cell-type specific
culture media. To assess the effect of the various treatments on cell population numbers,
cells were counted at the time of passage on day 4, reseeded at specific densities (635
cells/cm2 for hDFs and 1,500 cells/cm2 for hMLPCs) and counted again upon collection
(day 8). As hMLPCs typically grow slower and are maintained at a lower density than
hDFs the cell counts per defined area and population doublings (PDs) are expectedly
lower (Figure 3.9). The influence of small molecule and growth factor treatments on
hDFs is more pronounced than the effects of the same compounds on hMLPCs. VPA
treatment alone, SAH treatment alone, bFGF+VPA and bFGF+VPA+SAH treatments all
significantly lowered cell population counts in hDFs while hMLPCs were only affected
by VPA alone and VPA in conjunction with bFGF and SAH (Figure 3.9-A).

The

changes observed in total cell counts were also reflected by changes in the number of
PDs. hMLPCs demonstrated a 2-fold increase in the number of PDs in response to
bFGF+VPA+SAH treatment during days 0-4, while hDFs demonstrate significant
decreases in PDs following treatment under each condition. VPA had the most profound
effects on hDF PDs, a 1.75-fold decrease (Figure 3.9-B). VPA also induced decreases in
PDs during treatment days 4-8 in both hDFs and hMLPCs, as compared to untreated cell
groups (Figure 3.9-C). SAH, bFGF+VPA and bFGF+VPA+SAH treatments significantly
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decreased hDF PDs, while bFGF+VPA+SAH decreased hMLPC PDs (p < 0.05).
Interestingly the average population doubling of cell treatment populations during days 48 is relatively similar between hDFs and hMLPCs and much closer in range than during
days 0-4.

3.3 Competency of cells to respond to bFGF treatment: Cellular expression and
localization of FGFRs
3.3. Immunolocalization o f FGFRs and the effect o f cell treatments
In order to verify that hDFs and hMLPCs were competent to respond to bFGF
treatment, immunocytochemistry was used to determine the expression and localization
of the four FGFRs in hDFs, hMLPCs and hES cells. To verify that treatments did not
effect the expression of the receptors and therefore the cells’ ability to respond via these
receptors, both untreated and cells treated for 7 days with each 20 ng/mL bFGF, 1 mM
VP A, 0.5 mM SAH or combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH
were analyzed. FGFR antibodies were validated by immunoblotting to confirm protein
target size of the antibodies and revealed various isoforms expected in several of the
FGFRs (Figure 3.8). Some non-specific binding was present but can in-part be explained
by high antibody concentration levels used to saturate blots to be better able to visualize
protein. Densitometry was performed to normalize detection levels to compare relative
levels of FGFRs between cell types. Levels of FGFR 1 were similar between hESCs and
hMLPCs. In ICC samples, FGFR1 was localized to the ESC-derived fibroblast-like cells
that surround the hES cells colonies, which is consistent with results previously reported
(Bendall, et al., 2007; Stewart, et al., 2008) (Figure 3.10). Overall immunofluorescent
levels o f FGFR1 appeared to be higher in hMLPCs as compared to hDFs for both nuclear
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and cytoplasmic staining. hMLPCs also appeared to have detection of FGFR1 at the
plasma membrane, not present in hDFs. Interestingly, there appears to be two distinct
immunolocalization profiles in both hDFs and hMLPCs intermixed within each cell
population, one pattern showing prominent nuclear localization and the other a
cytoplasmic but non-nuclear localization. There was also punctate FGFR1 immunostaining in the perinuclear and pericellular regions of untreated, bFGF+SAH- and SAHtreated hMLPCs. The levels of FGFR1 detected also appeared to be higher in treatments
that contained bFGF.
Immunoblots revealed that hMLPCs had the highest detection of FGFR2, with
similar levels between hESCs and hDFs. Immunofluorescent labeling of FGFR2 showed
what appeared to be a weaker signal in hES cells as compared to hDF and hMLPCs as
well as stronger detection in MLPCs compared to hDFs (Figure 3.11). A strong punctate
staining pattern appeared in hDFs and hMLPCs across treatments, accompanied by strong
nuclear or perinuclear localization. hES cells have similar punctate staining, which
appeared to be mainly localized to the plasma membrane. FGFR2 detection levels
between cell types and treatment groups appeared to be consistent.
With reference to western blot densitometry, the levels of FGFR3 were similar
between

hESCs

and

hMLPCs

and

lower

in

hDFs

(Figure

3.8).

FGFR3

immunolocalization revealed strong staining across all cell types, appearing to be more
intense in hMLPCs as compared to hDFs. Direct comparison between treatment groups
reveals little influence of cell treatment on the immunolocalization of this receptor, which
appeared to be largely cytoplasmic (Figure 3.12). There is very strong FGFR3
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immunolocalization at hES cells cell periphery, but is absent from or very low in the
nucleus.
Relatively low levels of FGFR4 were detected across all cells types, though
appearing to be higher in hMLPCs as compared to hDFs, and minimal levels in hES cells
(Figure 3.13). In all cell types, staining appears to be localized to the plasma membrane
and was detected stronger and more punctate at various foci associated in/around the
nuclei in hMLPCs. Treatment of hDFs with either VPA or bFGF, or a combination,
results in increased immuno-detection of FGFR4. These findings contrast patterns
observed in hMLPCs in which FGFR4 appears to be lowest in untreated and VPA-treated
conditions and upregulated in all others.

Figure 3.9 Influence of treatments on cell numbers and population doublings. hDF
and hMLPC cells were treated with either 20 ng/mL bFGF, ImM VP A, 0.5mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH, supplemented in culture
media for 7 days. Cells were passaged at day 4, counted and reseeded specific densities
(635 cells/cm2 for hDFs and 1,500 cells/cm2 for hMLPCs). hMLPCs grow optimally at a
more sparse density than hDFs and thus have expectedly lower cell counts per area than
hDFs. A) hMLPCs appear to be less affected by treatments than hDFs. hDF cell number
is significantly decreased by VPA and bFGF+VPA+SAH treatment groups and hMLPC
numbers are decreased by VPA and bFGF+VPA+SAH treatments alone (*; p < 0.05), as
compared to untreated groups. (n=3). B) A similar, although less exaggerated pattern is
found when comparing hDF cell counts and the number of population doublings.
Significantly decreased PDs were induced by all treatments (*; p < 0.05). hMLPCs PDs
were significantly higher under bFGF+VPA+SAH treatments conditions, as compared to
untreated groups, during days 0-4. (n=3). C) The average population doubling of cell
treatment populations during days 4-8 is relatively similar between hDFs and hMLPCs
and much closer in range than during days 0-4. The largest magnitude of change was seen
in VPA treated groups for both hDFs and hMLPCs with a 4.3- and 1.86-fold change
respectively. Significant decreases in PDs were also observed in SAH, bFGF+VPA and
bFGF+VPA+SAH for hDF populations and bFGF+VPA+SAH for hMLPCs. (n=3).
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Figure 3.10 Immunolocalization of FGFR1 in hES cells, hDFs and hMLPCs. hDFs
and hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days before
paraformaldehyde fixing and immunolocalization with a mouse anti-human FGFR1
(Millipore) primary and Alexfluor488 (Invitrogen) secondary antibodies. FGFR1
localization at the periphery of hES cell colonies (indicated by white arrows). There was
an apparent and consistent higher immunofluorescent levels for FGFR1 detected in
hMLPCs compared to hDFs. There appears to be two distinct localization profiles in both
hDF and hMLPC within each population, differing by either the presence or absence of
nuclear staining, though always expressed in the cytoplasm. A rectangular arrow
indicates the presence of nuclear staining and its absence indicated by a triangular arrow.
The nuclear and cytoplasmic staining appeared to be higher in hMLPCs as compared to
hDFs. Also present was detection at what appeared to be the plasma membrane in
hMLPCs, though not in hDFs. There was also punctate immuno-staining in the
perinuclear and pericellular regions of untreated, bFGF+SAH- and SAH-treated
hMLPCs. FGFR1 staining appeared to be stronger in all treatments that contained bFGF.
Secondary only controls revealed no non-specific binding. Scale bar is equal to 100 p.m.
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Figure 3.11 Immunolocalization of FGFR2 in hES cells, hDFs and hMLPCs. hDFs
and hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days. Slides were
then fixed with paraformaldehyde and labeled with rabbit anti-human FGFR2 (Santa
Cruz) primary and Alexfluor488 (Invitrogen) secondary antibodies. Immunoflourescent
localization of FGFR2 shows what appears to be a more intense fluorescent signal in
hDFs and hMLPCs cells as compared to hES cells. Immunolocalization patterns appear
as punctate foci at the plasma membrane with strong detection at the nucleus and are
higher in MLPCs than dDFs. The staining of FGFR2 in hES cells appears to be largely
localized to the plasma membrane (indicated by arrows). There is punctate staining
pattern of this receptor with strong nuclear or perinuclear expression. The immuno
detection level between cell types and treatments appears to be relatively even.
Secondary only controls revealed no non-specific binding. Scale bar is equal to 100 pm.
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Figure 3.12 Immunolocalization of FGFR3 in hES cells, hDFs and hMLPCs. hDFs
and hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days before
paraformaldehyde fixing and immunofluorescent labeling with rabbit anti-human FGFR3
(Santa Cruz) primary and Alexfluor488 (Invitrogen) secondary antibodies.
Immunofluorescent detection of FGFR3 reveals high FGFR3 levels across all cell types.
There was a very strong immuno-detection level at hES cell membrane borders. There
appears to be stronger immuno-detection levels in hMLPCs compared to hDFs and fairly
even detection between cell treatments, which appeared to be localized to the cytoplasm.
Secondary only controls revealed no non-specific binding. Scale bar is equal to 100 pm.

FGFR3

Untreated

VPA

SAH

bFGF

bFGF+VPA

bFGF+SAH

bFGF+VPA+SA

Figure 3.13 Immunolocalization of FGFR4 in hES cells, hDFs and hMLPCs. hDFs
and hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH, supplemented in culture
media for 7 days before paraformaldehyde fixing and immunolocalization with rabbit
anti-human FGFR4 (Santa Cruz) primary and Alexfluor488 (Invitrogen) secondary
antibodies. Immunofluorescent detection reveals apparently higher levels of FGFR4 in
hMLPCs as compared to hDFs and minimal expression in hES cells. In all cell types,
staining appears to be localized to the plasma membrane and was detected stronger and
more punctate at various nuclei in hMLPCs. Treatment of hDFs with either VPA or
bFGF, or a combination, is followed by stronger immuno-detection. In hMLPCs FGFR4
appears to be lower in untreated and VPA-treated conditions. Secondary only controls
revealed no non-specific binding. Scale bar is equal to 100 p,m.
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3.4 Expression ofpluripotency factors and the influence o f cell treatments
3.4.1 Baseline levels ofpluripotency factors in hES cells, hDFs and hMLPCs
In order to provide a baseline pattern of pluripotency marker mRNA levels on
which to evaluate the effect of small molecule and growth factor treatments, it was
necessary to determine the baseline levels of various pluripotency factors. qRT-PCR was
used to determine steady-state mRNA levels in hES cells, hDFs and hMLPCs.
Transcripts for the various pluripotency markers were detected in all cell types, however
they were significantly lower in hDFs and hMLPCs compared to hES cells (Figure 3.15).
On average, OCT4 detection was about 250-fold lower, SOX2 was approximately 166fold lower, KLF4 5-fold lower and Nanog 100-fold lower in hDFs and hMLPCs
compared to hES cells. In hES cells Ct values ranged between 19 and 20 for OCT4, 21
and 22 for SOX2, 25 and 26 for KLF4 and 22 and 23 for Nanog. In hMLPCs and hDFs
Ct values for: OCT4 ranged between 29 and 34, SOX2 ranged between 31-32, KLF4
ranged between 25-27 and Nanog ranged between 30-35. Immunocytochemistry revealed
that pluripotency protein levels were also found to be relatively higher in hES cells
compared to hDFs and hMLPCs (Figures 3.16 - 3.19). Neither OCT4 (Figure 3.16) nor
Nanog (Figure 3.19) protein were detected at the protein level in hMLPC or hDF cell
types, although were strongly detected in hES cells. SOX2 protein was faintly detected in
hMLPCs displaying mostly a perinuclear immuno-localization pattern (Figure 3.17).
KLF4 was detected in both hDFs and hMLPCs, localized to the nucleus and an extranuclear structure whose location and shape is congruent with the endoplasmic reticulum
(Figure 3.18). Validation of pluripotency antibodies was determined by immunoblot to
determine antibody binding specificity by protein band size (Figure 3.14).
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Figure 3.14. Pluripotency factor antibody validation. Gel electrophoresis reveals the
size of proteins immuno-detected by anti-OCT4 (C-10, Santa Cruz), SOX2 (H-65, Santa
Cruz), KLF4 (H-180, Santa Cruz) and Nanog (ReproCELL) primary antibodies in hES
cell lysates (CA2). 10 pg of protein were loaded into 4-12% gradient Bis-Tris gels
(Invitrogen) and separated by protein size via electrophoresis. HRP-linked secondary
antibodies (Cell Signaling) and chemiluminescence induced by ECL substrate
(SuperSignal, ThermoScientific) were used to detect protein. Pluripotency protein bands
were observed at expected sizes, including the multiple banding pattern of KLF4.

Figure 3.15 Pluripotency transcript levels in hDFs, hMLPCs and hES cells. hDFs
and hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH, supplemented in culture
media for 7 days after which, cells were collected and RNA extracted. Transcript levels
for various pluripotency markers were determined by qRT-PCR within each untreated
cell type compared treated hDFs and hMLPCs. Data is presented normalized to the
housekeeping gene Cyclin G and expressed relative to human embryonic stem cells
(CA2), untreated hDFs and untreated hMLPCs. A) OCT4 transcripts were detected in all
three cell types, although significantly lower in hDF and hMLPCs as compared to hES
cells. There is no significant difference in OCT4 transcript levels between untreated cells
and 7 days post-treatment. B) SOX2 transcript abundance in hES cells is significantly
higher than hDFs and hMLPCs with no difference between hDF and hMLPCs or with
treatment. C) KLF4 was lower in hDF and hMLPCs than hES cells and decreased in
hDFs with VPA, SAH, bFGF+VPA, bFGF+SAH and bFGF+VPA+SAH treatments as
compared to untreated groups. There were no statistically significant differences in
expression of KLF4 across treated hMLPCs. D) While significantly less abundant in
hDFs and hMLPCs compared to hES cells, there was no change in Nanog transcript
levels with cell treatments. Data is presented as mean ± SEM. (p < 0.05) analyzed for
significance using one-way ANOVA. (n=3).
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Figure 3.16 Immunolocalization of OCT4 in hES cells, hDFs and hMLPCs. hDFs and
hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days before
paraformaldehyde fixation and immunofluorescent labeling with mouse anti-human
OCT4 (Santa Cruz) primary and Alexfluor488 (Invitrogen) secondary antibodies.
Immunolocalization of OCT4 was detected within the nuclei of hES cells but no
detectable OCT4 was apparent in hDFs or hMLPCs in any treatment group. Secondary
only controls revealed no non-specific binding. Scale bar is equal to 100 pm. (n=3).
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Figure 3.17 Immunolocalization of SOX2 in hES cells, hDFs and hMLPCs. hDFs and
hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days before
paraformaldehyde fixation and immunofluorescent labelling with rabbit anti-human
SOX2 (Santa Cruz) primary and Alexfluor488 (Invitrogen) secondary antibodies, which
revealed no detectable expression in hDFs. Strong SOX2 immunolocalization levels were
evident in the positive control, hES cells. Also observed was weak SOX2 detection in
untreated, SAH, bFGF, bFGF+VPA, bFGF+SAH and bFGF+VPA+SAH hMLPCs with
the strongest signal appearing to be in the bFGF+VPA+SAH group, indicated by arrows.
Where detected, signals were isolated to the perinuclear region. Scale bar is equal to 100
pm. (n=3).
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Figure 3.18 Immunolocalization of KLF4 in hES cells, hDFs and hMLPCs. hDFs and
hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VPA, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days after which
they were fixed with paraformaldehyde and immuno-labeled with rabbit anti-human
KLF4 (Santa Cruz) primary and Alexfluor488 (Invitrogen) secondary antibodies. KLF4
detection was present in all cell types, although apparently stronger in hES cells and
hMLPCs as compared to hDFs. Detection was mostly localized to the nucleus and
perinuclear region except in the cases of hMLPCs treated with bFGF and bFGF+VPA,
where increased cytoplasmic expression was detected, indicated by arrows. Scale bar is
equal to 100 p.m. (n=3).
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Figure 3.19 Immunolocalization of Nanog in hES cells, hDFs and hMLPCs. hDFs
and hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH for 7 days, followed by
paraformaldehyde fixing and with immunofluorescent labeling using rabbit anti-human
Nanog (ReproCell) primary and Alexfluor488 (Invitrogen) secondary antibodies. Nanog
protein is detected strongly in the positive control, hES cells, and with much less
fluorescent intensities in hMLPC treated with SAH, bFGF+SAH and bFGF+VPA+SAH
(indicated by white arrows). Scale bar is equal to 100 pm. (n=3).
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3.4.2 Influence o f small molecule and growth factor treatment on pluripotency transcript
levels in hDFs and hMLPCs.
Following a 7 day-treatment with 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH, cells were collected and
RNA extracted. Pluripotency marker transcript levels were determined by qRT-PCR to
compare mRNA levels between hES cells, hDF and hMLPC cells and untreated/treated
hDFs and hMLPCs to observe effect of treatments on pluripotency transcript levels.
There was no change in OCT4, SOX2 or Nanog transcript levels between untreated and
treated hDFs or hMLPCs, nor between treatment groups (Figure 3.15A,B,D; p < 0.05).
KLF4 transcript levels decreased in hDFs with VP A, SAH, bFGF+VPA, bFGF+SAH and
bFGF+VPA+SAH treatments as compared to untreated groups (p < 0.05, Figure 3.15-C)
while transcript levels in hMLPCs remained unaffected after treatments (p > 0.05).

3.4.3 Immunolocalization o f pluripotency markers in hDFs and hMLPCs and the
influence o f small molecule and growth factor treatments.
In order to ascertain whether the pluripotency transcript levels coincided with the
detection of their proteins, and to determine any potential effect of cell treatments on
pluripotency protein levels and localization patterns, immunocytochemistry was
conducted. OCT4 was not detected in either hDFs or hMLPCs in any treatment, but was
strongly detected in hES cells (Figure 3.16). SOX2, which was detected in hMLPCs in
the absence of treatment, is no longer detected in hMLPC samples that have been treated
with either VPA or bFGF alone (Figure 3.17). SOX2 levels do not appear to change
following all other treatments, where it is detected in the nucleus in hMLPCs. SOX2
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remained undetected in hDFs in all treatment groups. KLF4 protein was present in all cell
types, although it appeared to exhibit stronger immunofluorescent levels in hES cells and
hMLPCs as compared to hDFs (Figure 3.18). Detection was mostly localized to the
nucleus and perinuclear regions except in the cases of hMLPCs treated with bFGF and
bFGF+VPA, where cytoplasmic KLF4 was detected. Nanog detection, previously
undetected in neither hDFs nor hMLPCs, was detected in hMLPCs treated with SAH,
bFGF+SAH and bFGF+VPA+SAH, localized to both the nucleus and cytoplasm (Figure
3.19). The cellular response to treatment appeared to be quite consistent with the
detection of Nanog in 100% of hMLPCs treated with SAH, 94% of hMLPCs treated with
bFGF+SAH, and 99% treated with bFGF+VPA+SAH.
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CHAPTER FOUR: DISCUSSION

This study reveals that both human dermal fibroblasts (hDFs) and human multi
lineage progenitor cells (hMLPCs) express critical pluripotency transcripts at low levels
compared to human embryonic stem (hES) cells. SOX2 protein was detected in untreated
hMLPCs and not in hDFs. Treatment with s-adenosylhomocysteine (SAH) appears to
have facilitated the presence of Nanog protein without altering its mRNA transcript
abundance, though the mechanisms (promoting translation, stability ect...) with which it
accomplishes this remain unclear. Furthermore, Nanog protein was only detected in the
presence of SOX2 in hMLPCs.
Due to the biological, technical and ethical hurdles associated with the clinical
application of hES cells, the advent of iPS cells has created an entirely new field of
biotechnology that holds great potential for use as a research tool and for therapeutic
applications. The relatively few number of genes necessary to achieve the reprogramming
of somatic cells suggests that there are only a few principal upstream regulators for the
process of differentiation (Page, et al., 2009). The random integration of viral vectors and
the foreign DNA they carry cause a serious risk for tumourgenesis in the recipient
(Grabel, 2011). Many different techniques have been developed to minimize the impact
on the target cell genome including transiently expressed reprogramming factors, non
integrating episomal vectors and small molecule inhibí tors/activators (Walia, et al.,
2011). Various small molecules have been used to alter chromatin structure to
epigenetically activate genes that are essential for achieving and maintaining the
pluripotent state (J. Yu, et al., 201 la). Fibroblast growth factors, mediated via FGFRs, are
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also important in the regulation of hES cell self-renewal and critical for the maintenance
of pluripotency (Levenstein, et al., 2006). Less differentiated cells, such as progenitor
cells and adult stem cells innately express some of the critical pluripotency factors and so
may be more amenable to reprogramming (Pasha, et al., 2011). A major and largely
under-utilized source of immunologically and less differentiated naive cells is found in
post-partum umbilical cord blood. This study investigated the reprogrammability of a
multi-lineage cell (MLPC) population derived from neonatal human umbilical cord blood
and the influence of epigenetic factors in inducing or upregulating the expression of a
panel of pluripotency markers. We hypothesized that valproic acid (VPA) and sadenosylhomocysteine (SAH) would increase pluripotency factor expression in hMLPCs
in the presence of basic fibroblast growth factor suggesting that hMLPCs will be a more
readily reprogrammed to the pluripotent stem cell state than other traditionally used
differentiated cell types such as hDFs. To investigate this theory, it was first necessary to
determine the baseline expression of pluripotency factors in hMLPCs and hDFs
compared to the positive control hES cells.

4.1. Baseline expression o f pluripotency factors in hMLPCs as compared to hDFs and
hES cells.
Based on previous studies that utilized qRT-PCR to detect pluripotency factor
mRNAs in adult human dermal fibroblasts (Page, et al., 2009), it was expected that
transcripts for these factors would also be detected in both hDFs and the less
differentiated hMLPCs used in these experiments. Messenger RNA of each of the
pluripotency factors expressed in all cell types, though at very low levels compared to
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hES cells. The fact that cycle threshold (ct) values were within acceptable ranges (15-35),
and lends credibility to the validity of mRNA detection. In the case of OCT4, primers
were designed around at an exon-intron border to prevent the amplification of trace
genomic DNA contamination in samples. This design and the specificity of the primers
revealed by melt curve controls of hES cells lend support to the validity of OCT4
transcripts in hDF and hMLPC cells. Interestingly, while there was no significant
difference in the relative mRNA levels between hDFs and hMLPCs there was detection,
via immunocytochemistry, of SOX2 protein in hMLPCs, which was absent in hDFs
(Table 4.1). These results lend further support to the proposal by Page et al. (2009), that
the regulation of pluripotency may depend on post-transcriptional modifications as well
as de novo transcription and could change the focus of iPS technology to targets of
translational regulation. The innate expression of SOX2 in hMLPCs may be important for
the regulation of pluripotency transcription factor expression including OCT4 and Nanog,
as well as its own expression, similar to the transcriptional networks defined in murine
stem cells (Masui, et al., 2007). KLF4 was expressed relatively strongly in hMLPCs and
hDFs compared to other pluripotency factors, much closer to the levels seen in hES cells
and may also be important for the regulation of other pluripotency factors, including
Nanog (P. Zhang, et al., 2010). The detection of KLF4 in what appeared to be the
endoplasmic reticulum may indicate high levels of protein synthesis, important in the
regulation of other pluripotency factors (Bourillot & Savatier, 2010). Further
investigation could confirm this using an immunocytochemistry co-localization study,
tagging both KLF4 and calnexin, an endoplasmic reticulum protein involved in protein
folding. The less differentiated hMLPCs may be more amenable to pluripotency factor
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induction than hDFs, due to the baseline protein detection of several critical
reprogramming factors.

4.2 bFGF and FGFRs
bFGF and its ability to regulate hES cell proliferation (Levenstein, et al., 2006)
along with its capacity as a potent mitogen and morphogen in fibroblast populations
(Omitz & Itoh, 2001) has been extensively investigated. Recent studies have shown that
long-term treatments with bFGF results in increased proliferation and expression of hES
cell markers in human umbilical cord blood-derived multipotent stem cells

Table 4.1. Baseline expression of pluripotency factors in hES cells, hDFs and
hMLPCs.
F a c to r
O C T4

SOX2

KLF4

Nanog

Cell T y p e
hES cell
hDF
hMLPC
hES cell
hDF
hMLPC
hES cell
hDF
hMLPC
hES cell
hDF
hMLPC

mRNA
le ve ls
+++
+
+
+++
+
+
+++
++
++
+++
+
+

P ro te in
d e te cte d
+++
-

+++
-

+
+++
+
+
+++
-

Presence of pluripotency markers as detected at the mRNA level by qRT-PCR
and the protein level via immunocytochemistry. Strongly detected factors are denoted by
moderately expressed factors by *++’ and weakly detected factors by *+’;
denotes a lack of detection.
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(S. B. Park, et al., 2009) as well as in hDFs when used in conjunction with low oxygen
conditions (Page, et al., 2009). A longer duration of treatment or the addition of low
oxygen, which helps to regulate proliferation and pluripotency factor expression in
multiple cell types (Forristal, et al., 2010; Millman, et al., 2009; Zachar, et al., 2010), to
culture conditions may increase the effectiveness o f bFGF in promoting the expression of
pluripotency markers in hMLPCs. The increased population doubling with bFGF
treatment may in part be due to its role in maintaining genomic integrity via activation of
stress-induced DNA repair (Harfouche, et al., 2010). In this set of experiments, the
supplementation of bFGF into the culture media of hDFs and hMLPCs did not have the
expected effect on the population doublings of either hDFs or hMLPCs. Serums used in
culture media contain a mixture of growth factors so it is possible that the absence of
expected population expansion is due to the presence of sufficient bFGF in the serum,
which has already activated this feedback loop making cells insensitive to further bFGF
supplementation. Alternatively, bFGF and low oxygen conditions cooperatively effect
cell proliferation, and so bFGF alone, without low oxygen, may not have been sufficient
to create expected effects (Nurse & Vollmer, 1997). It appears that increased
concentrations of bFGF are however able to induce changes in cell morphology, resulting
in the spindle-like morphological changes seen in hDFs in these experiments and
previously published reports (Page, et al., 2009).
Since the effect of bFGF in reprogramming is likely mediated by FGFRs at the
plasma membrane (Page, et al., 2009), another possible explanation for our findings is the
level and localization of FGFRs in hDFs and hMLPCs. The punctate staining patterns
observed in several of the FGFRs may represent internalization of the receptors inside
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cytoplasmic vesicles, important for their action in some cases. All four FGFRs were
detected in hES cells as previously shown (Bendall, et al., 2007). FGFRs were also
detected in hDFs and hMLPCs, demonstrating that both hDFs and hMLPCs are
competent to respond to bFGF treatment. There were different levels of the various
isoforms detected in all cell types which may explain, in part, the different patterns of
expression levels between the immunoblots and ICC imaging (another explanation are
provided in the limitations and future directions section of this report). FGFR1, strongly
expressed in perimeter cells of hES colonies, identifies niche cells derived by the stem
cell colony itself (Stewart, et al., 2008). Functioning as an autologous source of growth
factor secretion, these cells may be an important source of bFGF production for the
maintenance of the pluripotency of hES cells (Dvorak, et al., 2005). FGFR1, whose
activation upregulates epidermal growth factors (Bade, et al., 2011), is expressed in hDF
and hMLPCs in what appear to be distinct subpopulations, those that reveal nuclear
localization of FGFR1 and those in which FGFR1 is absent from the nucleus. This may
indicate that there are cells within populations with diverging expression profiles that
could be more competent to respond to bFGF signaling at the nuclear membrane. This
could have important implications in the transcriptional regulation of pluripotency factors
or may identify a subpopulation of bFGF-sensitive support cells functioning similarly to
the fibroblast-like periphery cells in hES colonies. The increased detection of FGFR1 in
bFGF treated cells is congruent with Park and Yu et al. (2009), who reported both an
increase in FGFR1 and OCT4 expression with the treatment of bFGF. The discrepancy
between Park and Yu et al. and this study may be explained by differences in cell type
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and the bFGF used to treat cells was twice the concentration used in this study at 40
ng/ml.
Another important FGFR in the context of pluripotency is FGFR2. This receptor
is considered to be one of the primary signaling mechanisms for bFGF and acts by
promoting cell adhesion and survival rather than directly maintaining pluripotency
(Eiselleova, et al., 2009). The detection of FGFR1 and FGFR2 in hMLPCs parallel the
expression of these receptors in porcine umbilical cord where they act as bFGF signaling
conduits for the production of extracellular matrix components in myofibroblasts and
smooth muscle cells, as well as providing proliferative and migration signals in
endothelial cells of various vessel types (Chrusciel, et al., 2010). A suggested action of
bFGF-induced increases in proliferation is the positive feedback regulation of bFGF and
IGFs, which has been shown to enhance the IGF-mediated pluripotent and differentiation
potentials in hUCB multipotent stem cells (S. B. Park, et al., 2009). Neither FGFR3 nor
FGFR4 has been fully characterized in developmental roles but have shown to be
involved in regulating cell growth and division in healthy and wounded human epidermal
tissue (Takenaka, et al., 2002) and the initiation of mammalian liver development (Jung,
et al., 1999) respectively. The high detection of FGFR3 in hES cells, hMLPCs and hDFs,
localizing in the nucleus in the more differentiated cell types, indicate an important
function in these cells, despite the fact that it is not a main target for bFGF and
preferentially binds acidic FGF (Chen & Hristova, 2011). Reportedly binding bFGF with
high affinity (Ron, et al., 1993), FGFR4 is expressed higher in hMLPC cells than hDFs
and interestingly VP A treatment has the opposite effect on the two cell types, increasing
expression in hDFs and decreasing it in hMLPCs. In addition to acting as a signaling
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complex with bFGF, it has also been reported that FGFRs can interact with cell adhesion
molecules (Cavallaro, et al., 2001; Christensen, et al., 2011), important for stem cell
colony formation and the maintenance of pluripotency. Cell-adhesion molecules have
important functions in pluripotency and reprogramming, providing spatial cues that
cross-talk with essential transcription factors (Stepniak, et al., 2009)JRecently, the viral
transfection of E-cadherin, which is crucial for embryonic stem cell pluripotency, has
been shown to replace exogenous OCT4 in the reprogramming process (Redmer, et al.,
2011). Since VPA has been shown to affect certain adhesion molecules, both increasing
adhesion o f VPA-treated cells (Walmod, et al., 1999) and disrupting adhesion to the
extracellular matrix (Jones, et al., 2009), this area may warrant further investigation.
While, exogenous bFGF supplemented into culture media stimulates hES cells via
the FGFRs, endogenous bFGF can exert different functions depending on its subcellular
localization (Dvorak, et al., 2005). Certain isoforms may be targeted to the nucleus,
operating in an intracrine manner independently of cell-surface receptors, while others
may be exported from fibroblast cells and act via FGFRs as an autocrine or paracrine
factor.

Signaling via the FGFRs may be more critical for the maintenance of

pluripotency because the inhibition of FGFRs suppresses activation of downstream
protein kinases leading to widespread and rapid hES cell differentiation (Dvorak, et al.,
2005). The nuclear localization of these receptors in hDFs and hMLPCs may implicate a
role of bFGF at the level of chromatin in human cells (Page, et al., 2009) as previously
demonstrated in its involvement in chromatin remodeling in rat cortical neuron
progenitor cells (Song & Ghosh, 2004). While transcriptional activation of OCT4 and
SOX2 is not bFGF dependent, the growth factor is critical for the maintenance of
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expression of these pluripotency factors, via its receptor (Levenstein, et al., 2006). A
proposed method of action is a regulatory loop involving the TGF-(3 pathway, important
in many cellular processes including cell growth and differentiation. This signaling
pathway acts via ligands to maintain the expression of OCT4, SOX2 and Nanog, which
subsequently activate the expression of bFGF (Greber, et al., 2007).
Due to the detection of all four FGFRs throughout the cells it is unlikely that the
lack o f increased proliferation in hDFs and hMLPCs upon treatment with bFGF is due to
FGFR localization that would prevent ligand binding and complex formation for
signaling. It is more likely that bFGF naturally occurring in culture serum may have
previously provided proliferative signal results that further supplementation would not
have increased after a certain concentration (Makino, et al., 2010). Further exploration of
this observation could be more quantitatively assessed through tritiated thymidine
incorporation or bromodeoxyuridine labeling assays (K. Zhang, et al., 2011; Zheng, et al.,
1997).

4.3 Evaluation o f the impact o f treatments
VPA can epigenetically modify chromatin structure by selectively inhibiting the
catalytic activity of class I HDACs and induce proteasomal degradation of F1DAC2,
which leads to more open transcriptionally active DNA (Hezroni, et al., 2011; Kramer, et
al., 2003) thereby regulating cell fate. In addition to its general effect on chromatin
structure, VPA has been shown to enhance the OCT4 promoter activity in murine
myogenic cells directly targeting its hormone response element located within the
proximal region of the OCT4 promoter via nuclear hormone receptors (Teng, et al.,
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2010). Past studies have shown VPA’s ability to facilitate the reprogramming of cells to a
pluripotent state, replacing the use of exogenous transgenes with endogenous epigenetic
regulation (Debeb, et al., 2010; Huangfu, et al., 2008a; Medvedev, et al., 2011; Plews, et
al., 2010). In this study, the use of comparable dosage did not increase the expression of
any pluripotency factors at the RNA or protein level with treatment of VP A, alone or in
conjunction with any other treatments. Surprisingly, VPA treatment instead decreased the
mRNA expression of KLF4 and the protein detection of SOX2. Whether this was due to
direct intervention or action via other indirect factors cannot be determined without
further studies, however SOX2 has been shown to be affected by acetylation, where an
increase cellular acetylation leads to reduction in Sox2 levels by ubiquitination and
proteasomal degradation (Baltus, et al., 2009). Evidence in the literature also suggests
that VPA can induce growth arrest, apoptosis and senescence in human medullablastoma
cell lines by increasing histone hyperacetylation and regulating genes involved in cell
cycle control (X. N. Li, et al., 2005a). Apart from their roles in the acetylation of
histones, HDACs can promote the acetylation of transcription factor proteins such as p53
(Vigushin & Coombes, 2002), a gene known to be responsible for senescence and
apoptosis. The senescent morphological appearance of hDFs and the decrease in
population size of both cell types at higher concentrations of VPA, support the possibility
that instead of upregulating pluripotency factors VPA treatment may have lead to the
acetylation of p53, which would further activate transcription through recruitment of
coactivators and histone acetyltransferases, crucial for p53 function (Bariev, et al., 2001).
Due to the conflicting evidence in the literature and the studies presented here on the role
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of VPA in promoting the expression of pluripotency factors further investigation is
warranted and will be discussed later on in this paper.
In addition to histone acetylation, DNA methylation also has an important role in
the epigenetic regulation of genomic expression and therefore cell fate. While quite
cytotoxic, 5-azacytidine and 5-aza-2'-deoxycytidine have been utilized foremost among
drugs for the decrease of DNA methylation (Christman, 2002). To mediate their effect on
DNMTase, 5-azacytidine and 5-aza-2'-deoxycytidine must be incorporated into the DNA
structure (Creusot, et al., 1982). At low, non-lethal doses DNMTase activity is
compromised due to an irreversible binding necessitating new enzyme synthesis to
reverse the block of DNA methylation (Taylor & Jones, 1982). As an underutilized
alternative, SAH has been used to help facilitate the nuclear reprogramming process of
fibroblast donor cells in somatic cell nuclear transfer by inducing global DNA
demethylation

(Jeon,

methyltransferase

et al., 2008).

active site than

SAH, having

a higher

SAM, its precursor,

affinity for the

inhibits most cellular

methyltransferase via cellular and intracellular accumulation. In agreement with previous
studies done in fibroblasts, the SAH dose response conducted for this study demonstrated
that 0.5 mM SAH has the highest effect on global DNA demethylation in hMLPCs. There
were also no apparent effects on cell morphology and a slight increase in cell population,
revealing no negative effect of SAH on cell proliferation, which can be a concern due to
possible aging acceleration caused by random DNA demethylation (Gray, et al., 1991).
The increased detection of pluripotency factor protein without an increase in the
abundance of transcripts indicate post-transcriptional and post-translational mechanisms
which are indirectly regulated by SAH-induced DNA demethylation and may help
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elucidate information on the regulation of the hES cell transcriptome. Central to the
regulation of gene expression are transcription factors, controlled via an interconnected
transcriptional circuit that is structured by epigenetic modifiers and refined by posttranscriptional events (Cassar & Stanford, 2011). Post-transcriptional regulation of gene
expression includes mRNA processing, splicing, editing, transport, stability and
translation (Sharova, et al., 2009). Degradation of mRNA is an important component of
gene function that controls the steady-state concentration of functional transcript levels in
the cell (Raghavan & Bohjanen, 2004). The absence of several pluripotency markers at
the protein level despite the presence of corresponding mRNA transcripts, as well as
changes in protein expression patterns without the modification of mRNA levels may be
explained by a lack of pluripotency mRNA stability (Ross, 1995). As shown in
mammalian primary cell lines, mRNA half-lives are significantly altered during cell
differentiation, though can be stabilized by various cytokines and growth factors (Ross,
1995). The degradation of pluripotency mRNA could also explain the low levels found in
hMLPCs and hDFs as compared to hES cells.
While expressed at the mRNA level, the detection of Nanog protein was only
possible under the treatment of SAH. The known role of SOX2 as a driving force in the
expression of several pluripotent-specific genes, including Nanog, (Rodda, et al., 2005;
Young, 2011) was apparent in our studies since Nanog was only detected in samples that
also expressed SOX2 (Table 4.2) and was only frequently detected in the nucleus treated
with bFGF+SAH. It is possible that Nanog protein is being translated from mRNA
transcripts but is quickly and therefore not detectable. A potential post-translational
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Table 4.2. Impact of small molecule and growth factor treatment on pluripotency
marker protein detection.

Treatment

OCT4

SOX2

KLF4

Nanog

hDF

hMLPC

hDF

hMLPC

hDF hMLPC

hDF

hMLPC

untreated

-

-

-

+

+

+

-

-

VPA

“

-

-

-

+

+

-

-

SAH

-

-

-

+

+

+

-

+

bFGF

-

-

-

+

+

+

-

-

bFGF+VPA

-

-

-

+

+

+

-

-

bFGF+SAH

-

-

-

+

+

+

-

+

bFGF+VPA+SAH

-

-

-

+

+

+

-

+

Presence of pluripotency marker is indicated by a *+’ if present and a

if absent.

mechanism that would effect the stability of Nanog protein is the phosphorylation of
serine or threonine followed by proline residues, which change the protein conformation
and allow for the interaction of the prolyl isomerase Pinl, leading to stabilization of
Nanog by suppressing ubiquination (Moretto-Zita, et al., 2010). KLF4 may also be
important for the presence of Nanog protein due to its role as a regulator of Nanog
expression in hES cells helping to prevent cellular differentiation (P. Zhang, et al., 2010).
Because KLF4 was detected in all cell types and treatments it is difficult to discern its
direct effect on the other pluripotency factors in this study. However, as an inhibitor of
differentiation, KLF4’s strong presence is important for reprogramming, due to its role in
the dynamics of pluripotency. Nanog, an important upstream regulator of pluripotency,
binding to hundreds of target genes to regulate their expression (Jauch, et al., 2008), is
endogenously up-regulated during the intermediary stages of reprogramming, after which
it is essential to achieve the pluripotent state by stabilizing the major players in the
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pluripotency gene regulatory network (Silva, et al., 2009). Recently, murine myoblasts,
endogenously expressing SOX2, KLF4 and cMYC, were successfully reprogrammed to a
pluripotent state with only a HDAC inhibitor after 5 days of treatment, followed by 3
weeks o f culture under embryonic stem cell conditions (Pasha, et al., 2011). Perhaps with
extended SAH/bFGF treatment periods and/or embryonic stem cell culture conditions,
Nanog protein signals might have increased and maintained long enough for the
relationship between SOX2, Nanog and the elusive but critical OCT4, to synergistically
promote auto-regulated protein-coding and upregulation of mRNA, bringing hMLPCs
closer to the pluripotent state without the use of transgenes.

4.4 Limitations o f study andfuture directions
With regard to the series of experiments contained in this study there are a number of
limitations that need to be acknowledged and addressed. Firstly, sample sizes in several
experiments were comparatively small, including relative methylation levels with SAH
treatment and FGFR localization ICC studies. Larger sample sizes generally provide
increased precision and more accurately reflect the influence of treatments on
populations. The future of this project lies partially in increasing sample size and
performing identical experiments on a different hMLPC clonal population to ensure
results observed are not an isolated incident. This is especially true when attempting to
explain what appear to be anomalous findings in the case of the SAH methylation dose
response. I am currently unable to explain the increase in methylation at the higher
concentrations of 2 mM and 4 mM. Due to the sample size I cannot perform statistics nor
with any certainty claim a trend of increasing methylation at higher concentrations.
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Repeating this experiment with a larger sample size would help to refute or confirm
findings and from there either troubleshoot problems with the protocol or elucidate
molecular mechanisms to explain this tendency. If this trend is genuine it could
potentially be explained by the relationship between DNA méthylation and apoptosis, in
which changes in DNA méthylation patterns particularly in the promoter region of genes
either in the form of hypomethylation or hyperméthylation can have profound effects on
gene expression (Gopisetty, et al., 2006). This would correlate with the decrease in
populations also seen in the higher concentrations of SAH.
ICC cell counts indicating the presence or absence of pluripotency factors were
unfortunately only completed on the final sets of slides. Inclusion of multiple counts
would increase experimental support of conclusions made based on these numbers.
Conducting Western Blots on the pluripotency factors could also help quantify
pluripotency protein levels, especially in the case here, in which cellular response to
treatment appears to be quite consistent.
Some technical issues that were present in this study include the anti-FGFR
antibodies. Although specific for FGFR targets there was also some non-specific binding
revealed by immunoblotting. Strong signals were difficult to obtain via immunoblot, as
compared to ICC, which could be explained by inefficient protein transfers, and so higher
than ideal concentrations of anti-FGFR antibodies were used to obtain signals intense
enough to be effectively compared between cell types. The higher concentrations of
antibodies could cause exaggerated non-specific binding. The low signals also
necessitated the loading of large amounts of protein, whereby (3-actin signals were also
increased and in some cases overexposed despite extremely short exposure timeframes.
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Due to what appear to be divergent effects of VPA on pluripotency factor mRNA
and protein levels it is important to elucidate the mechanisms by which VPA is acting
both on chromatin structure and specific promoters. The first step would be confirming
the action of VPA as an inhibitor of HDACs, which could be accomplished by western
blotting using antibodies against histone H3 and acetylated histone H3 at lysine 9 and 14.
More specific patterns could be determined via chromatin immunoprécipitation (ChIP)
followed by promoter specific PCR, which can be used to map the localization and levels
o f post-transcriptionally modified histones (Sohi, et al., 2011). This technique could also
be used to observe influences of VPA on specific transcription factors, or to determine
the specific location in the genome that various histone modifications are associated with,
indicating the target o f histone modifiers, important for both acetylation and
déméthylation. The global DNA méthylation analysis performed in this study could also
be confirmed using bisulphite sequencing of various promoters to both confirm the
déméthylation status of the DNA and determine its pattern of méthylation, important in
determining if the chromosome at the location of a gene of interest is being opened to
enable transcription.
Despite recent evidence in the literature with regard to the detection of low levels
o f pluripotency factors in somatic cells types (Page, et al., 2009) it still remains a point of
contention amongst various scientific groups. Although OCT4 oligonucleotide primers
were designed to prevent the amplification of genomic DNA, and typical controls
including melt curves and no-template controls were normal, in future experiments I
recommend running both a negative control, something confirmed to have no
pluripotency gene expression and an mRNA control, which would ensure that there was
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no genomic DNA contamination in the samples before cDNA generation. A subsequent
precaution would also be to use agarose gel electrophoresis to ensure that the amplicons
from the qRT-PCR reaction were the correct size. These steps would make it more
convincing that OCT4 expression at low levels in somatic cell types is a valid assertion.
Even with the previously listed techniques, it is difficult to make an association
between post-translational mechanisms and SAH-induced DNA demethylation to
describe possible post-transcriptional / post-translational regulation of pluripotency
factors that explain the increased detection of certain pluripotency factors after treatment
without any significant increase detection of pluripotency transcripts. ChIP could be used
to investigate post-translational influences on the specific promoter of genes of interest
that may in turn be involved in regulating protein level of pluripotency factors to help
elucidate posttranslational mechanisms, which at present remain largely unknown. If a
post-translational regulator of Nanog were identified one could look at the effect of SAH
induced demethylation on the promoter of the gene. The next step would be to investigate
if this is concordant with the mRNA and protein levels of the gene because even if
transcription is affected by SAH this must translate into protein for an observable effect
on the pluripotency factor. Alternatively, cycloheximide, a protein synthesis inhibitor,
could be used to prevent protein translation ensuring that quantification of remaining
protein would indicate the lack of degradation, or protein stability (Ramakrishna, et al.,
2011). Treating cells with cycloheximide and assaying for the detection of protein, using
either immunocytochemistry or immunoblotting techniques, at various timepoints along
the half-life of each protein would indicate how much protein remained and assess
protein stability changes between non-treatment and treatment groups.

91
Important future directions of study would be to extend SAH treatment or modify
protocols to include a period of maintenance under hES cell culture conditions to allow
for the expansion of preliminary gene/protein regulation observed in this set of
experiments. Research strategies to assess the normalcy of the cells in order to identify
partial or complete reprogramming and ensure resultant cells are safe and efficient
sources for potential clinical therapies or disease modeling would also be important for
the furthering of hMLPCs for use in iPS technology.

4.5 Rejection o f initial hypothesis
With the results of this study I am forced to reject my hypothesis that valproic
acid and s-adenosylhomocysteine will increase the levels of pluripotency factors in
hMLPC in the presence of basic fibroblast growth factor due to the fact that the
observable effects of each treatment were not to increase mRNA levels of any
pluripotency factor in either cell type. We did see surprising indirect SAH-induced
changes in pluripotency factor protein detection. My objectives were met in that I was
able to confirm the presence of FGFRs 1, 2, 3 and 4, and with a certain degree of
confidence determine the relative baseline levels of pluripotency factors in hMLPCs and
hDFs compared to hES cells. I completed my second objective in part, determining that
global DNA demethylation does have an impact on the presence of pluripotency markers
SOX2 and Nanog, though the mechanisms by which both SAH and VPA work still need
to be determined.
In summary, as an alternative to the tumourgenic random-integration of viral
transgenes in other types of reprogramming, hMLPCs, which are a relatively young,
naive cell type, easily accessible at the time of birth, commonly banked and which
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endogenously express more pluripotency proteins than hDFs, may be a more amenable
cell type for direct reprogramming. This may be due in part to the synergistic,
autoregulatory relationships between endogenously expressed SOX2

and other

pluripotency factors. The expression and function of pluripotency mRNA and protein
represent different points on the flow of genetic information and are dynamically
produced and degraded, suggesting that in regulating the cell state there are mechanisms
in addition to transcription that must be considered in safe and efficient reprogramming.
MicroRNAs (miRNAs), a class of small, non-coding RNAs, are post-transcriptional
regulators that target and bind messenger RNA transcripts with great specificity,
suppressing translation through degradation of targets (S. L. Lin, et al., 2010). ES cell
specific miRNAs are downregulated as ES cells differentiate, while other miRNAs are
low in hES cells but highly upregulated during differentiation (Houbaviy, et al., 2003).
miRNA 145 directly targets and represses the 3’ untranslated regions of OCT4, SOX2,
and KLF4 transcripts, inhibiting hES cell self-renewal, repressing expression of
pluripotency genes, and inducing lineage-restricted differentiation (Xu, et al., 2009).
OCT4, in turn, binds and represses the miR-145 promoter in hES cells indicating a
fundamental and integrated role in the regulation of pluripotency (Xu, et al., 2009). The
miRNA 302, conversely, functions to repress specific epigenetic regulators to enhance
global demethylation through suppression of downstream DNMTases (S. L. Lin, et al.,
2010). miRNA 367 works to activate OCT4 expression (Anokye-Danso, et al., 2011),
while miRNA 302 functions to promote the positive autoregulatory loop of OCT4,
NANOG and SOX2 that is crucial for maintaining the undifferentiated state (Judson, et
al., 2009; Rosa & Brivanlou, 2011). Recently, induced expression of several different ES
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cell-specific miRNAs (302 and 367), combined with small molecule treatments,
efficiently produced iPS cell colonies (Anokye-Danso, et al., 2011; S. L. Lin, et al.,
2010), demonstrating not only that miRNAs are key participants in the generation and
maintenance of pluripotency, but that transcriptional as well as post-transcriptional
regulation of stem cell factors is necessary for efficient reprogramming.
Due to the integrated function of pluripotency factors, functional KLF4 and SOX2
may be critical for the protein expression of Nanog and together may promote the
expression/post-transcriptional regulation of OCT4, which is necessary for footprint-free
reprogramming, in a given time and under appropriate conditions. Subpopulations within
clonal populations that are more able to respond to reprogramming due to receptor
profiles and pluripotency factor localization could be isolated and may reveal an efficient
response to small molecule treatments. For epigenetic reprogramming, SAH and small
molecules used for the inhibition of HDACs are important to induce transcription of
silenced pluripotency genes (Huangfu, et al., 2008a; Shi, et al., 2008a), although VPA is
not be the ideal candidate to accomplish this as it is a possible activator of apoptosis and
senescent-promoting genes. bFGF appears to promote the correct localization of
pluripotency factors for influencing the expression profile of the cell through direct
chromatin interaction and signaling through its various receptors (FGFRs), which may
play key roles in the maintenance of pluripotency in signaling at both the plasma and
nuclear membranes. iPS cells provide a unique opportunity to study mechanisms of
pluripotency in humans that has not before been possible. They also have unparalleled
promise for use in regenerative medicine that may lead to the restoration of form and
function in many incurable human diseases.
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APPENDIX: SUPPLEMENTAL FIGURES

hMLPC

hDF

Figure S-l. RNA integrity confirmed by formaldehyde electrophoresis gel. hDF and
hMLPC cells were treated with either 20 ng/mL bFGF, 1 mM VP A, 0.5 mM SAH or
combinations of bFGF+VPA, bFGF+SAH or bFGF+VPA+SAH, supplemented in culture
media, for 7 days after which, cells were collected an RNA extracted from samples and
hES cells cells as a positive control, separated on a formaldehyde-agarose gel, stained
with ethidium bromide and UV illuminated. RNA is of sufficient quality to proceed with
qPCR based on separation of 18S and 28S RNA bands and their size. (n=l).
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Figure S-2. RT-qPCR validation of KLF4 primer set. A 5-fold dilution series was
used to create a four-point standard curve in order to assess the efficiency of the primer
pair. Ideal conditions are efficiency of 100% (E = 100.7%), Coefficient of determination
of 1 (R2 = 0.992), and a slope equal to -3.3 (Slope = -3.305). n=l, in 3 technical
replicates.

Ill

Figure S-3. Melt curves of hES cell pluripotency factor qPCR. Melting curves were
analyzed to verify the specificity of the PCR reactions (absence of primer dimers and
nonspecific products of amplification). Single peaks represent only one amplicon being
amplified. n=3.

Figure S-4. VPA has a negative impact on cell density by treatment day 4. Culture
media supplementation of VPA at higher concentrations of 2mM and 4mM appears to
have a greater influence on cell populations of hDFs as compared to hMLPCs.
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FGFR3

FGFR4
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Figure S-5. Validation of FGFR antibodies - entire immunoblot. Gel electrophoresis
reveals the size of proteins immuno-detected by anti-FGFR primary antibodies. 30 p,g of
protein were loaded into 7.5% Bis-Tris gels and separated by protein size via
electrophoresis. Anti-FGFRl antibody (Millipore) and anti-FGFRs 2, 3 and 4 (Santa
Cruz) were used to immuno-detect the receptors in cell lysates of hES cells, hMLPCs and
hDFs. HRP-linked secondary antibodies (Cell Signaling) and chemiluminescence
induced by ECL substrate (SuperSignal, ThermoScientific) were used to detect protein.
Anti-P-actin (Sigma) was used as a loading control between samples. Receptors were all
detected in each cell type within the range of the expected size for all FGF receptor
proteins but there was also some non-specific binding present. This can in part be
explained by high antibody concentration levels used to saturate blots to be better able to
visualize protein

